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Abstract 
 
Following recurrent hypoglycaemia (RH) patients with type 1 diabetes (T1D) 
may develop an impaired counter-regulatory response (CRR) to future 
hypoglycaemic episodes. This is a result of maladaptive responses to 
hypoglycaemia, involving AMP-activated protein kinase (AMPK) activity in the 
ventromedial hypothalamus (VMH). Research has focused mainly on 
glucosensing neurones, with little emphasis on the potential role of astrocytes. 
This study aims to examine the response of astrocytes to a hypoglycaemic 
stimulus and changes to this following RH. 
The U373 human astrocytoma cell line and mouse primary cortical astrocytes 
(CRTAS), as well as wild type (WT) and α1/α2 AMPK knockout (KO) mouse 
embryonic fibroblasts (MEF), were used. Astrocytes were maintained at 25mM 
glucose, and stepped down to physiological (2.5mM) glucose for the 
experiments. Western blotting was used to measure total and phosphorylated 
protein expression. Luminescence and absorbance plate-based assays were 
used to measure ATP and lactate levels, respectively. A plate-based assay was 
used to measure intracellular calcium ([Ca2+]i) using Fluo4. 
Our study demonstrates that astrocytes intrinsically respond to a hypoglycaemic 
stimulus by increasing AMPK activation. Following RH there was a blunted 
AMPK activation, accompanied by a reduction in extracellular ATP (eATP). 
Using the AMPK activator, A-769662, we saw a concentration-dependent 
increase in AMPK activation and eATP. However, enhancing AMPK activation 
by co-application of A-769662 and 5-aminoimidazole-4-carboxamide riboside 
(AICAR), or by exposing astrocytes to a hypoglycaemic stimulus in the 
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presence of A-769662, did not enhance ATP release. A-769662 also caused an 
increase in [Ca2+]i. Both the A-769662-mediated increase in eATP and [Ca
2+]i 
persisted in MEF α1/α2 AMPK KO cells. The effect of A-769662 on eATP was 
not attenuated by pre-treating cells with the gap junction blocker carbenoxolone, 
or by removing extracellular Ca2+, however there was a small attenuation 
following pre-treatment with the [Ca2+]i chelator, BAPTA-AM. 
In our study we show that astrocytes intrinsically respond to a hypoglycaemic 
stimulus by increasing phospho AMPK (pAMPK). Following RH, the AMPK 
response to hypoglycaemia is blunted, alongside a significant reduction to 
eATP. We also demonstrate that the changes in eATP observed are likely 
independent of changes in AMPK activity. Importantly, the AMPK activator, A-
769662, has AMPK-independent effects on eATP and [Ca2+]i, and these 
changes in eATP are mediated by changes in [Ca2+]i. 
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Chapter 1: Introduction 
1.1   Diabetes and hypoglycaemia 
1.1.1   Diabetes mellitus  
 
Diabetes is a metabolic disorder characterised by lack of effective glycaemic 
regulation. Cells are unable to take up sufficient glucose, resulting in elevated 
blood glucose (over 7 mM fasted or over 11 mM 2-hour post-prandial glucose). 
The kidneys are unable to reabsorption all the glucose back into the circulation, 
leading to loss of glucose through the urine, and rapid weight loss. Chronically 
elevated blood glucose levels can lead to micro- and macrovascular 
complications and substantially reduce life expectancy. There are two main 
types of diabetes mellitus, Type 1 (T1D) and Type 2 diabetes (T2D).  
 
T1D often starts during childhood and is caused by the loss of β-cell function in 
the pancreas (Alberti and Zimmet, 1998). These cells are responsible for the 
production of insulin in response to elevated blood glucose concentrations. The 
cause for this cell loss is not yet fully understood, however it is now known that 
at least 1-2% of diabetes cases are due to monogenic diabetes, whereby 
inherited or sporadic mutations in a single gene linked to β-cell function cause 
the disease (Naylor et al., 2011). Environmental factors, such as viral infection 
are also believed to be a trigger for the development of T1D; in fact, T1D is 
strongly associated with autoimmune activity (Richardson et al., 2011; Willcox 
et al., 2011). Most T1D patients, with the exception of some types of monogenic 
diabetes, rely on insulin injections to maintain euglycaemia. 
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T2D is characterised by the combination of a decrease in insulin secretion and 
decrease in insulin sensitivity. This is believed to be caused by a variety of 
genetic predispositions combined with the effect of lifestyle habits, such as 
overeating, lack of exercise and obesity (Unoki et al., 2008; Voight et al., 2010; 
Yasuda et al., 2008). T2D usually develops later in life, although the age of 
onset has been decreasing over the past few years, potentially due to the 
increase in childhood obesity (Ogden et al., 2007). T2D can often be managed 
by changes in lifestyle, such as diet and exercise, as well as using oral 
medication, such as the biguanide metformin, or sulphonylureas; However in 
advanced T2D, where significant β-cell loss has occurred, insulin injections may 
be necessary.  
 
In both T1D and T2D it is crucial to maintain tight glycaemic control. High blood 
glucose levels can result in a number of long-term microvascular (retinopathy, 
nephropathy and neuropathy) as well as macrovascular complications. This can 
in turn result in sight loss, renal failure and gangrene, as well as an increased 
risk for arteriosclerosis which may lead to stroke, myocardial infarction and 
occlusive artery disease of the lower extremities. Hyperglycaemia can also 
result in a variety of acute complications such as ketoacidosis and 
hyperosmolar syndrome, which can lead to loss of consciousness, coma and, in 
extreme cases, death (Alberti and Zimmet, 1998). Whilst trying to achieve tight 
glycaemic control and avoid these side-effects of hyperglycaemia, people on 
insulin treatment might use a higher dose than necessary, which increases the 
risk of experiencing a hypoglycaemic episode (less than 4mM blood glucose).  
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1.1.2   Hypoglycaemia 
 
Even though insulin has been used as a treatment for diabetes since 1922 
(Banting et al., 1922), insulin-induced hypoglycaemia (blood glucose below 
4mM) remains a serious side effect and is the limiting factor in maintaining tight 
glycaemic control. Severe hypoglycaemia is defined as a hypoglycaemic 
episode where assistance from another individual is required (Donnelly et al., 
2005). The symptoms of hypoglycaemia can be separated into two categories, 
neurogenic and neuroglycopenic. Neurogenic symptoms result from the 
activation of the autonomic nervous system and normally precede the 
neuroglycopenic. The increase in cholinergic signalling can cause symptoms 
such as sweatiness, hunger and tingling, and the increase in adrenergic 
signalling can cause tremulousness, palpitations and anxiety. They function to 
alert the individual of hypoglycaemia. Neuroglycopenic symptoms are a result of 
glucose deprivation in the brain and include warmth, weakness, confusion and 
tiredness (Towler et al., 1993). If no corrective action is taken they can lead to 
coma and even death. Hypoglycaemia therefore has the potential to be acutely 
life-threatening, making glycaemic control challenging in insulin-dependent 
diabetes patients. 
 
One dangerous aspect of hypoglycaemia is what is referred to as the dead-in-
bed (DID) syndrome (Tattersall and Gill, 1991), where the patients are found 
dead in their, usually, undisturbed bed. DID due to hypoglycaemia is 
responsible for 5-6% of deaths in patients suffering with T1D under 40 years old 
(Cryer, 2011; Koltin and Daneman, 2008; Tanenberg et al., 2010). Through 
continuous glucose monitoring and other post-mortem examinations, DID 
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appears to be due to a nocturnal hypoglycaemic episode (Koltin and Daneman, 
2008; Tanenberg et al., 2010). T1D patients often have defective counter-
regulatory (CRR) hormone release, accompanied by a defective awakening 
response to nocturnal hypoglycaemia (Banarer and Cryer, 2003; Schultes et al., 
2007). It is suggested that a nocturnal hypoglycaemic episode from which the 
patient does not wake up, may result in severe neuroglycopenia, brain damage 
and death. Another suggestion is that a nocturnal hypoglycaemic episode 
results in a fatal cardiac arrhythmia (Chow et al., 2014; Clark et al., 2014; Gill et 
al., 2009; Tanenberg et al., 2010). Apart from the dangers posed by 
hypoglycaemia itself, the fear of experiencing a hypoglycaemic episode can 
lead to complications as well, as it can result in patients maintaining a higher 
glycaemic level than recommended in order to avoid it (Bloomgarden, 2016; 
Cryer, 2002). 
 
1.1.3   Hypoglycaemia detection 
 
Hypoglycaemia is detected by glucosensing neurones both in the periphery and 
in the brain. Peripheral glucosensors have been identified in the hepatic portal-
mesenteric vein (PMV) and the carotid body, as well as the gut and oral cavity. 
Glucosensing neurones in the PMV can detect changes in glucose and relay 
the message through the vagus nerve and spinal cord back to the central 
nervous system, to areas such as the hypothalamus, to elicit a response (Watts 
and Donovan, 2010). Central glucosensing neurones are spread throughout the 
brain, but are most highly expressed in specific loci associated with the 
regulation of food intake, energy metabolism, neuroendocrine function and 
energy homeostasis. These areas are the hypothalamus, specifically, the lateral 
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hypothalamus and ventromedial hypothalamus (VMH), and the hindbrain, 
especially the area postrema, the nucleus of the solitary tract and the dorsal 
motor nucleus of the vagus (Watts and Donovan, 2010). Thanks to its 
positioning adjacent to the third ventricle (3V) and median eminence, the 
hypothalamus can directly sample the blood glucose and circulating hormones 
such as insulin and leptin, to elicit a response (Beall et al., 2012a). 
 
Two main types of glucosensing neurones have been identified in the brain, 
glucose excited (GE) and glucose inhibited (GI) neurones (Oomura et al., 
1969). In these neurones, glucose does not only act as fuel, but also acts as a 
regulator to activate or inhibit neuronal activity in GE and GI neurones 
respectively. These neurones have been compared to α and β-cells in the 
pancreas, as they both share a number of characteristics in the mechanism in 
which they respond to changes in glucose (Ashford et al., 1990; Dunn-Meynell 
et al., 2002). Both glucosensing neurones and β-cells express the glucose 
transporter GLUT3 and GLUT2, as well as the glucokinase enzyme (GK). The 
majority of GE neurones also express the ATP-sensitive K+ channel (KATP), 
which play a crucial part in glucosensing (Ashford et al., 1990). The GLUT2 
transporter, GK and the KATP channel are required in both these neuronal and 
pancreatic cells in order to respond to changes in glucose (Balfour et al., 2006). 
AMP-activated protein kinase (AMPK) is also expressed in both cell types, and 
genetic ablation of its α2 subunit in GE neurones or pancreatic β cells abolishes 
their ability to respond to hypoglycaemia (Beall et al., 2012b; Beall et al., 2010).  
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1.2   Defective counter-regulation 
1.2.1   The counter-regulatory response (CRR) 
 
As blood glucose concentration falls in a healthy individual, a number of 
counter-regulatory mechanisms are initiated. Once blood glucose levels fall 
below approximately 4.44mM, endogenous insulin release is suppressed 
(Wendt et al., 2004; Zhou et al., 2007).This is followed by an increase in 
glucagon secretion from pancreatic α-cells at glucose levels of approximately 
3.8mM, which acts to stimulate hepatic glucose production by increasing 
glycogenolysis and gluconeogenesis and therefore increases blood glucose 
levels (Ishihara et al., 2003). This is accompanied by the activation of the 
sympathetic and parasympathetic autonomic nervous system, causing an 
increase in noradrenaline and adrenaline release. Noradrenaline acts on nerve 
terminals to produce some of the symptoms of hypoglycaemia. Adrenaline is 
released into the circulation and activates alpha and beta adrenergic receptors 
to sustain blood glucose concentrations. This effect is mediated by further 
inhibiting insulin release and promoting glucagon release from the pancreas, as 
well as reducing glucose uptake and utilisation in muscles, further increasing 
gluconeogenesis and glycogenolysis in the liver and increasing lipolysis in 
adipose tissue (Avogaro et al., 1993). Further decreases in glucose result in the 
release of growth hormone (at 3.7mM blood glucose) and cortisol (at 3.2mM 
blood glucose). These have not been shown to directly improve blood glucose, 
but are believed to have more long-term effects. They induce gluconeogenesis 
and ketogenesis in the liver as well as lipolysis in adipose tissue (Fanelli et al., 
1994; Mitrakou et al., 1991; Schwartz et al., 1987). 
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In the brain, glucose concentration differs significantly from peripheral blood 
glucose; However, it still parallels that of the periphery. In the brain, 
euglycaemic glucose levels range between 0.7-2.5mM. During peripheral 
hypoglycaemia, brain glucose falls to 0.2-0.5mM and during hyperglycaemia it 
can go up to 5mM (Karnani and Burdakov, 2011; Silver and Erecinska, 1994). 
Inducing local hypoglycaemia in the VMH using 2-deoxyglucose has been 
shown to induce the CRR, resulting in increased peripheral glucose, glucagon, 
adrenaline and noradrenaline (Borg et al., 1995). This indicates that 
glucosensors in the brain can induce the CRR independently during 
experimental central hypoglycaemia, even in the presence of peripheral 
euglycaemia.  
 
1.2.2   Impaired counter-regulation 
 
Patients with T1D do not release endogenous insulin, and thus inject 
exogenous insulin to regulate their blood glucose levels. This means that there 
is no mechanism to switch off or inhibit this insulin if glucose levels fall. After 
approximately 5 years the glucagon response in these individuals is often 
diminished, leaving them highly reliant on the adrenaline response to 
hypoglycaemia (Segel et al., 2002). Following recurrent hypoglycaemia (RH) 
episodes however, patients can develop an impaired CRR to hypoglycaemia 
(also referred to as hypoglycaemia-associated autonomic failure (HAAF)) where 
the threshold for the adrenaline response to hypoglycaemia becomes higher, 
giving those patients less time from the appearance of symptoms to taking 
corrective action. Impaired hypoglycaemia awareness affects approximately 
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20% of people with T1D and increases the risk of experiencing a severe 
hypoglycaemic episode by over 2-fold (Geddes et al., 2008). 
 
Previous hypoglycaemia is a significant predictor of future hypoglycaemia 
(Donnelly et al., 2005). Studies on T1D and T2D patients, as well as healthy 
controls, have demonstrated impaired CRR to hypoglycaemia following even a 
single recent hypoglycaemic episode (Arbelaez et al., 2008; Joy et al., 2015; 
Segel et al., 2002). These studies have also been replicated in animal models 
(LaGamma et al., 2014; McCrimmon et al., 2006). The impaired CRR to 
hypoglycaemia has been shown to be reversible through avoidance of 
hypoglycaemia, with improvements seen following 2 weeks of hypoglycaemia 
prevention, and near complete normalisation of CRR following 3 months of 
hypoglycaemia avoidance (Fanelli et al., 1993). This provides further evidence 
that hypoglycaemia itself, is responsible for impaired CRR and that this effect is 
reversible. 
 
Even though the involvement of the central and peripheral nervous system in 
glucosensing and the development of impaired counter-regulation has been 
long established, the underlying mechanism is still unknown. Nicotinic 
acetylcholine (nACh) neurones in the chromaffin cells in the adrenal glands are 
activated during hypoglycaemia, promoting the biosynthesis and release of 
adrenaline. One theory behind the impaired CRR is that prolonged or repeated 
activation of these nAChR through full agonists, such as insulin, causes a 
maladaptive response to antecedent hypoglycaemia. Indeed, studies on rats 
showed that a partial activation of peripheral nAChR using the partial agonist, 
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cytisine, increases de novo catecholamine synthesis and greatly restores the 
hormonal response to hypoglycaemia (LaGamma et al., 2014). 
 
Basal gamma aminobutyric acid (GABAergic) tone in the VMH prevents 
adrenaline and glucagon secretion during euglycaemia and hyperglycaemia. 
This needs to be suppressed in order to initiate the hormonal response to 
hypoglycaemia (Zhou et al., 2010). Rats exposed to RH or rat models of Type 1 
diabetes have an increased GABA baseline, by 3-fold and 2-fold respectively, 
measured through brain microdialysis, meaning that inhibition of GABA release 
during hypoglycaemia is not sufficient to allow adrenaline and glucagon release 
(Chan et al., 2008; Chan et al., 2013). Lactate has been shown to raise GABA 
levels in the VMH, and has also been shown to inhibit the CRR. Since inhibiting 
lactate transport from astrocytes or preventing its uptake and utilisation by 
neurones prevents lactate-mediated impairment in CRR, it is possible that an 
increase in brain lactate drives the increase in basal GABA levels, and thus 
prevents counter-regulatory hormone release (Borg et al., 2003; Zhou et al., 
2010). 
 
1.3   AMP-activated protein kinase (AMPK) 
1.3.1   Whole body energy homeostasis 
 
AMP-activated protein kinase (AMPK) has also recently been shown to be 
involved in the CRR to hypoglycaemia. In the past decade, AMPK has been 
established as a cellular energy sensor involved in whole body energy 
homeostasis and has been shown to be involved in the response to 
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hypoglycaemia. It was first described in two different cellular processes by 
independent groups in 1973 (Beg et al., 1973; Carlson and Kim, 1973). The 
same enzyme was discovered to be responsible for both processes (Carling et 
al., 1987), and was later named AMPK (Sim and Hardie, 1988). 
 
AMPK is composed of a catalytic α-subunit and regulatory β- and γ-subunits. In 
mammals, two α-subunits (α1, α2), two β subunits (β1, β2) and three γ-subunits 
(γ1, γ2, γ3) have been identified (Carling, 2004) (Figure 1.1). AMPK is activated 
through phosphorylation on the threonine 172 (Thr172) residue of the α-subunit 
by a variety of AMPK kinases (AMPKK) (Carling, 2004), such as the tumour 
suppressor kinase, LKB1, (Hawley et al., 2003), TGF-β-activating kinase 1 
(TAK1) (Herrero-Martin et al., 2009) and the intracellular calcium sensor, 
calcium calmodulin-dependent protein kinase kinase  (CaMKK) (Gowans et 
al., 2013; Hawley et al., 2005; Hurley et al., 2005; Woods et al., 2005). AMPK is 
also regulated by changes in the intracellular AMP:ATP ratio (Corton et al., 
1994). AMP and ATP both bind to the γ-subunit of AMPK, the former of which 
binds at a much higher affinity than the latter, mediating opposing effects; ATP 
inhibits AMPK activation, whilst AMP increases AMPK activation through direct 
allosteric activation (Gowans et al., 2013; Scott et al., 2004). AMP as well as 
ADP also protect AMPK from dephosphorylation (Xiao et al., 2011).  
 
AMPK is involved in the regulation of a variety of cellular processes, such as 
proliferation, autophagy, phagocytosis and energy homeostasis. AMPK 
phosphorylation of the Thr172 residue on the α-subunit has been shown to 
decrease during hyperglycaemia and increase during hypoglycaemia or fasting  
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Figure 1.1. General AMPK structure and some of its modulators. AMPK is made up of a 
catalytic α subunit and regulatory β and γ subunits. The physiological regulators of AMPK, 
CaMKKβ, TAK1 and LKB1 phosphorylate AMPK on the α subunit, and ATP and AMP inhibit 
and activate AMPK respectively through the γ subunit. The AMPK activator AICAR gets 
converted to ZMP once inside the cell, which acts as AMP mimic through the γ subunit. The 
AMPK activator A-769662 binds to the βsubunit to mediate its effect. 
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(Taib et al., 2013). It acts to increase catabolic processes such as glucose 
uptake, glycolysis and fatty acid oxidation and uptake, while simultaneously, 
decreasing anabolic processes, such as protein, glycogen and fatty acid 
synthesis, to promote energy production and increase ATP (Scott et al., 2014). 
AMPK activation has been shown to decrease blood glucose and lipid levels by 
increasing glucose transport into the cells, and fatty acid oxidation, while 
inhibition has been shown to raise them (Bergeron et al., 2001; Cool et al., 
2006), making it an important regulator of whole body energy homeostasis, and 
a potential therapeutic target for a variety of metabolic diseases.  
 
AMPK has also been associated with diabetes. During both hyperglycaemia 
and hypoglycaemia, experienced in T1D and T2D, AMPK activity is altered, and 
evidence suggests AMPK activation may be beneficial for both. The AMPK 
activator A-769662 has been shown to be beneficial for both hepatic steatosis 
and insulin resistance in animal models, two characteristics of T2D, as well as 
for maintaining more physiological levels of blood glucose and lipids (Cool et al., 
2006). Studies in rats also suggest central AMPK activation may be beneficial 
for restoring the defective CRR to hypoglycaemia (McCrimmon et al., 2006; 
McCrimmon et al., 2004), suggesting AMPK may have potential as a 
therapeutic target for treatment of diabetes. 
 
1.3.2   AMPK and the counter-regulatory response 
 
The involvement of AMPK in peripheral glucose homeostasis has long-been 
established. It has been shown that knocking out AMPK in animals results in 
reduced glucose tolerance, insulin resistance and increased fatty acids (Viollet 
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et al., 2003), whereas overexpression in the liver causes a reduction in blood 
glucose, and increased fatty acid oxidation (Foretz et al., 2010). AMPK is also 
essential for β-cell KATP channel opening during hypoglycaemia, which is 
required for β-cell glucosensing (Ashcroft and Rorsman, 1990; Beall et al., 
2013). Studies on mice with pancreatic AMPK α2 deletion showed impaired 
glucose homeostasis and glucose-stimulated insulin secretion (GSIS), which 
was exacerbated in mice also lacking α1 AMPK. Cultured islets from both 
genotypes of mice had a decreased GSIS as well as an attenuated ability to 
supress insulin secretion in low glucose (Beall et al., 2010). This indicates that 
β-cells require AMPK in order to respond to both high and low glucose. Cultured 
islets have a decreased AMPK phosphorylation in response to high glucose, 
and pharmacologically activating AMPK supresses the GSIS. In agreement to 
this, introducing a constitutively active AMPK mutation in β-cells inhibits GSIS, 
whereas, a dominant negative mutation causes insulin release during 
hypoglycaemia (da Silva Xavier et al., 2003). Taken together, this data suggests 
that AMPK regulation is necessary for glucosensing and controlled insulin 
secretion in β-cells. 
 
1.3.3   AMPK in glucosensing neurones 
 
AMPK is known to be essential for mediating the CRR to hypoglycaemia in the 
periphery; However, increasing evidence suggests that it is also essential for 
the central regulation of glucose. Both β-cells and glucosensing neurones have 
been shown to share multiple similarities in their response to changes in 
glucose. Both cell types require KATP activity (Ashcroft and Rorsman, 1990; 
Beall et al., 2012b), as well as GK and GLUT2 (Balfour et al., 2006) for 
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glucosensing. One of the main glucosensing areas in the brain is the 
hypothalamus, with the VMH playing an important role in glucosensing and 
responses to energy availability, as well as other homeostatic processes 
(Karnani and Burdakov, 2011; Routh et al., 2014). Similarly, to the pancreas, 
hypothalamic AMPK activation increases during hypoglycaemia (Han et al., 
2005). Pharmacologically inhibiting this hypothalamic AMPK activation or 
genetically downregulating VMH AMPK expression, attenuates the CRR to 
hypoglycaemia (Han et al., 2005; McCrimmon et al., 2008). Inversely, activating 
VMH AMPK amplifies glucose production and the CRR during hypoglycaemia 
(McCrimmon et al., 2006; McCrimmon et al., 2004). Studies on a cell line of 
hypothalamic GE neurones, GT1-7 cells, showed a decrease in AMPK 
phosphorylation when exposed to high glucose (Taib et al., 2013). Similarly to 
the observation made in β-cells, reducing AMPK α2 activity in GT1-7 cells, 
blunts their response to hypoglycaemia (Beall et al., 2012b). This suggests that 
central, and more specifically, neuronal glucosensing requires AMPK for the 
detection of both high and low glucose. The involvement of AMPK in neuronal 
glucosensing has been studied extensively, however, glial AMPK involvement in 
this mechanism has been overlooked. A large body of evidence implicates the 
involvement of glia, especially astrocytes, in the response to both hyper- and 
hypoglycaemia (Lam et al., 2005; Marty et al., 2005; Taib et al., 2013).  
 
1.4   Glial cells 
1.4.1   Glial cells support neuronal function 
 
Glial cells were originally considered the “glue” of the brain; However, over the 
years, they have been shown to be involved in a multitude of processes. There 
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are three types of glial cells, oligodendrocytes, microglia and astrocytes.  
Oligodendrocytes form the myelin sheath around neuronal axons, microglia act 
as the innate immune system of the brain and astrocytes were initially thought 
of as the “housekeeping” cells in the brain. (Figure 1.2) 
 
Astrocytes regulate neuronal activity, maintain ion balance in the extracellular 
space, remove neurotransmitters, and provide neurones with nutrients, such as 
lactate (refer to section 1.6). Astrocytes form what is referred to as the “tripartite 
synapse” by enveloping the post- and pre-synaptic nerve terminal of a synapse, 
with astrocytic processes (Araque et al., 1999). This allows them to detect and 
modulate neuronal transmission. Each astrocyte is also in contact with a blood 
vessel through astrocytic end-feet (Kacem et al., 1998). This allows astrocytes 
to monitor the synaptic environment and bloodstream simultaneously, and thus 
modulate synaptic activity, as well as the entry of substances through the blood-
brain barrier.  One essential function of astrocytes, is their ability to take up 
glutamate released into the synaptic cleft by neurones, convert it to glutamine, 
and export it back into the extracellular medium for neurones to take up and 
recycle back into glutamate stored in vesicles. This is referred to as the 
glutamate-glutamine cycle. Prolonged glutamate stimulation of neurones can 
have excitotoxic effects, meaning that glutamate uptake by astrocytes is a very 
important process in maintaining neuronal health, as well as replenishing 
neuronal glutamate stores (Broer and Brookes, 2001). For recent review on 
neuroglial signalling see (Gundersen et al., 2015). 
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Figure 1.2. Schematic drawing of neuronal and glial interactions. Oligodendrocytes 
(yellow) make myelin and wrap neuronal (green) axons. Microglia (purple) make contact with 
neurones. Astrocytes (blue) envelop neuronal synapses and send processes to blood vessels 
(red). 
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One important function of astrocytes is the production and export of lactate. 
Even though glucose is thought of as the main energy substrate for neuronal 
metabolism, studies suggest that neurones may preferentially use lactate (Beall 
et al., 2012b; Song and Routh, 2005). Astrocytes express glucose transporters, 
predominantly GLUT1 (Iwabuchi et al., 2014), allowing glucose uptake; 
However, unlike neurones, astrocytes express low levels of pyruvate 
dehydrogenase (PDH), suggesting that they are geared towards glycolysis 
rather than oxidative metabolism of glucose (Laughton et al., 2007). Astrocytes 
also express high levels of lactate dehydrogenase (LDH), especially LDH1 and 
LDH5, of which the latter is almost exclusively expressed in astrocytes and has 
a higher affinity for pyruvate than lactate, meaning it preferentially converts 
pyruvate to lactate (Laughton et al., 2007). Lactate can then be exported 
through monocarboxylate transporters (MCT), of which MCT1, MCT2 and 
MCT4 are expressed in astrocytes (Pellerin et al., 2005). Astrocytes can also 
produce lactate from glutamate taken up from the synaptic cleft. Astrocytes also 
express glycogen synthase (GS) which converts glucose to glycogen, and 
glycogen phosphorylase (GP), which breaks down glycogen stores. This 
suggests that astrocytes can use the glucose taken up from the extracellular 
medium and store it as glycogen, which can be broken down and exported as 
lactate during periods of energy stress to sustain neurone activity (Brown et al., 
2003; Suh et al., 2007; Swanson and Choi, 1993; Walls et al., 2008). 
Breakdown of astrocytic glycogen stores to release lactate has also been 
demonstrated in normoglycaemia during intense exercise in rats (Matsui et al., 
2015). This has also been shown in long-term potentiation and memory-
formation (Newman et al., 2011), suggesting that it is not only important in 
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pathophysiological conditions, but in physiological high energy demand 
activities. 
 
1.4.2   Astrocytes: More than a supporting role 
 
Even though astrocytes play an important role in supporting neuronal function 
through removal of potentially excitotoxic neurotransmitters from the 
extracellular space and providing neurones with energy, they have also been 
shown to be directly involved in the modulation of neurotransmission in a variety 
of physiological and pathophysiological processes. Astrocytes release a variety 
of gliotransmitters, such as GABA, D-serine, TNFα, ATP, glutamate and lactate, 
which can propagate a signal across astrocytic populations, mediate effects on 
other cells in the brain, such as microglia and oligodendrocytes, or modulate 
synaptic transmission and plasticity (Araque et al., 2014; Araque et al., 1999; 
Bezzi and Volterra, 2001; Gundersen et al., 2015). 
 
Hypothalamic astrocytes are glucosensing cells and act to modulate the 
response to both hypoglycaemia and hyperglycaemia. They respond to 
changes in glucose by changing AMPK activity (Taib et al., 2013). A glucose 
injection in the carotid increases insulin release accompanied by an activation 
of astrocytes in the arcuate nucleus (ARC). Inhibiting this activation of 
astrocytes inhibits the insulin response to glucose (Guillod-Maximin et al., 
2004). A different group has showed that this activation of the hypothalamo-
pancreatic axis by carotid glucose injection requires the conversion of glucose 
to lactate, as well as pyruvate metabolism, indicating the potential involvement 
of astrocytes (Allard et al., 2013). The two major glucose transporters 
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expressed in astrocytes are GLUT1 and GLUT2. Astrocytes predominantly 
express GLUT1, although, hypothalamic astrocytes specifically, highly express 
GLUT2 (Iwabuchi et al., 2014). GLUT2 KO mice have impaired sensitivity to 
both hyper- and hypoglycaemia, and fail to initiate a glucagon response and 
brainstem c-Fos activation following peripheral or central 2DG-mediated 
hypoglycaemia. This was rescued by re-expressing GLUT2 in astrocytes, but 
not neurones (Marty et al., 2005). This indicates that astrocytic GLUT2 plays an 
important role in the detection and response to hypoglycaemia. In 
streptozotocin (STZ)-induced diabetic rats, GLUT1 expression was reduced in 
hypothalamic astrocytes. This was accompanied by defective hypothalamic 
glucosensing. Overexpressing GLUT1 in hypothalamic astrocytes was able to 
reverse this (Chari et al., 2011). Another astrocyte-like type of cell found in the 
hypothalamus that has been shown to be glucosensing is tanycytes. These 
cells line the 3V in the hypothalamus, placing them in direct contact to glucose 
and hormones in the CSF, and send projections into the ARC and VMH, areas 
involved in energy homeostasis, and exhibit ATP-mediated responses to 
glucose (Frayling et al., 2011). Taken together, this evidence suggests that 
astrocytes play an essential role in central glucosensing. 
 
1.5   Adenosine triphosphate (ATP) 
1.5.1   ATP as a gliotransmitter 
 
ATP was originally viewed solely as the source of cellular energy; however, it is 
now accepted that extracellularly, ATP acts as a neurotransmitter acting on a 
large family of receptors, known as the purinergic P2 receptors, to modulate a 
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multitude of processes throughout the body. The action of ATP as a 
neurotransmitter was first proposed by Burnstock in 1972 (Burnstock, 1972). 
 
Extracellular ATP is a universal “danger signal “, causing inflammatory 
responses, such as cytokine release and recruitment of immune cells (Idzko et 
al., 2014). It acts as a fast excitatory neurotransmitter, mediating short-term 
effects, as well as long-term effects on proliferation, growth and development 
(Burnstock, 2006b; Idzko et al., 2014). ATP can be released through a variety of 
regulated mechanisms such as vesicular release or through channels, or 
passively as a result of damage to the cell wall. Once released, ATP is 
hydrolysed by ectonucleotidases, into AMP, ADP and adenosine, from which, 
ADP and adenosine, can in turn activate other purinergic receptors (Idzko et al., 
2014) (Figure 1.3). 
 
Most ectonucleotidases are membrane-bound, either by expressing membrane 
helices, or through anchorage to the membrane, although soluble forms have 
also been reported. There are four main families of ectonucleotidases in 
mammalian cells, ectonucleotiside triphosphate diphosphohydrolase (ENTPD), 
ectonucleotide pyrophosphatase/phosphodiesterase (ENPP), alkaline 
phosphatase, and ecto-5’-nucleotidase (also known as CD73). Each of these 
preferentially hydrolyses different nucleotides with different affinities. Seven 
ectonucleotidases have been discovered in the ENTPD family (ENTPD1-6 and 
8), of which only four hydrolyse nucleotides (ENTPD1-3 and 8). These 
ENTPDases hydrolyse ATP and ADP to AMP. In the ENPP family, three have 
been characterised (ENPP1-3), which hydrolyse ATP to AMP and 
pyrophosphate. Alkaline phosphatase hydrolyses ATP, ADP and AMP to  
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Figure 1. 3. Overview of purinergic signalling. ATP is broken down to ADP and AMP by 
ectonucleoside triphosphate diphosphohydrolase (E-NTPDase), to AMP by ectonucleotide 
pyrophosphatase/phosphodiesterase (E-NPP) and to adenosine (Ado) by alkaline 
phosphatase. Alkaline phosphatase also breaks ADP or AMP down to adenosine. CD73 
breaks AMP down to adenosine. ATP activates P2X and P2Y receptors. UTP, ADP, UDP and 
UDP-glucose (UDPg) activate P2Y receptors. Adenosine activates adenosine (P1) receptors 
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adenosine, and CD73 hydrolyses AMP to adenosine. For recent reviews: 
(Yegutkin, 2008; Zimmermann et al., 2012). These nucleotides, and the 
nucleoside, adenosine, as well as UTP, UDP and UDP-sugars, act on 
purinergic receptors to elicit a wide variety of responses.  
 
Purinergic receptors are split into two categories, P2X and P2Y receptors. In the 
P2X receptor family, 7 subunits have been cloned, P2X1-7.  P2X receptors are 
plasma membrane channels that can form heterotrimers or larger heteromeric 
complexes. They are activated by ATP and are permeable to small monovalent 
and divalent cations, such as Na+, K+ and Ca2+. This entry of Ca2+ upon channel 
activation initiates the Ca2+ signalling cascade. The P2X7 receptor acts in a 
biphasic mode, where upon initial activation, it acts as a cation channel, 
however, following prolonged activation, forms a pore, which is permeable to 
small molecules, including ATP, glutamate and GABA (Suadicani et al., 2006). 
This receptor has been linked to a variety of pathologies, such as temporal lobe 
epilepsy, neurodegenerative disorders, neuropathic pain, diabetes, and cancer 
(Burnstock, 2006a). The P2Y receptor family is composed of 8 subtypes, P2Y1, 
2, 4, 6, 11-14. These are G-protein-coupled receptors and upon activation either 
activate PLC-β, raising intracellular calcium, or activate or inhibit adenylate 
cyclase, depending on the G protein coupled to each receptor. ATP binds to all 
P2Y receptors except for P2Y6 and 14. P2Y11 binds ATP exclusively. P2Y1, 12 
and 13 also bind ADP, and P2Y2, 4 and, to a lesser extent, P2Y6 bind UTP. 
P2Y6 mainly binds UDP and P2Y14 binds UDP-glucose and other UDP-sugars. 
Adenosine activates a separate type of receptors, adenosine (also known as 
P1) receptors, of which there are four subunits, ADORA1, ADORA2A, 
ADORA2B and ADORA3 (Burnstock, 2006a, b; Idzko et al., 2014).  
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1.5.2   ATP release from astrocytes 
 
Astrocytic ATP release is important in modulating neuronal and astrocytic 
activation in several, if not all, brain regions (Bowser and Khakh, 2004; Gourine 
et al., 2010; Koizumi et al., 2003). There is some disagreement regarding the 
method of ATP release from astrocytes (Hamilton and Attwell, 2010), with 
studies suggesting it is through connexin (Cx) or pannexin (Px) hemichannels, 
P2X7 receptors, vesicles, volume regulated anion channels (VRAC) or cystic 
fibrosis transmembrane conductance regulators (CFTR).  
 
Astrocytic vesicular ATP release is believed by some to be the main mechanism 
behind astrocytic ATP release (Bowser and Khakh, 2007; Lalo et al., 2014). 
Astrocytes can store ATP in vesicles, mainly lysosomal vesicles, although some 
ATP appears to also be stored in smaller vesicles. The lysosomal-associated 
vesicular nucleotide transporter (VNUT) is expressed in astrocytes, and is 
believed to be responsible for astrocytic ATP release (Oya et al., 2013). 
Activation of purinergic currents in pyramidal neurones by astrocytic ATP 
release is abolished in astrocytes expressing dominant negative soluble N-
ethylmaleimide-sensitive-factor attachment protein receptor (DN-SNARE), 
indicating that vesicle fusion is necessary for astrocytic purinergic stimulation of 
neurones (Lalo et al., 2014). 
 
ATP can also be released by the P2X7 receptor. This receptor has been 
associated with a variety of pathologies (Burnstock, 2006a), as well as with 
ATP-induced cell lysis and apoptosis, and the mediation of immune responses 
(Arulkumaran et al., 2011). This receptor has been shown to be permeable to a 
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variety of small molecules of up to 1KDa, including ATP, glutamate and GABA. 
This only occurs after prolonged activation, when the channel changes 
conformation into a pore (Surprenant et al., 1996). Studies have suggested that 
this receptor, is responsible for ATP-induced ATP release, and thus Ca2+ 
propagation (Suadicani et al., 2006). 
 
Hemichannels are another mechanism through which ATP can be released. 
These are channels organised in a hexamer, formed by connexins or 
pannexins, and are referred to as connexons or pannexons, respectively. 
Pannexins can only form hemichannels, whereas, connexins from adjacent cells 
can join to form gap junctions allowing direct intracellular exchange between 
astrocytes (Bennett et al., 2003; Giaume et al., 2010; Lazarowski et al., 2011). 
When activated, hemichannels are permeable to small molecules, up to 1-
1.2kDa, such as ATP. These channels are also permeable to small dyes, which 
are often used to examine the function of these channels. Astrocytes mainly 
express Cx43 and Cx30 (Dermietzel et al., 1991; Giaume et al., 1991), although 
mRNA receptor expression of other Cx subunits has been reported (Blomstrand 
et al., 2004). The ATP secretion from poorly coupled cell lines, such as C6, 
U373 and HeLa can be increased by inducing the expression of Cxs. This 
increase in ATP release involved the mobilisation of Ca2+ stores in astrocytes 
and the action of Cl- channels (Cotrina et al., 1998).  
 
ATP release has also been shown to be mediated by other channels, often 
overlooked when studying astrocytic ATP release, the VRAC. According to a 
study by Anderson et al, ATP-induced ATP release in primary cortical 
astrocytes did not involve changes in [Ca2+]i, and was not inhibited by blocking 
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vesicular release, or hemichannels. However, it was blocked by anion channel 
blockers. It was suggested that ATP release may be through VRAC (Anderson 
et al., 2004a). 
 
1.5.3   Calcium signalling in astrocytes 
 
Unlike neurones, astrocytes do not exhibit action potentials, but instead 
communicate through gliotransmission and Ca2+ waves. ATP-induced ATP 
release is crucial for Ca2+ wave propagation (Bowser and Khakh, 2007; Cotrina 
et al., 1998) (Figure 1.4). Mechanical stimulation of astrocytes initiates Ca2+ 
wave propagation and inhibits excitatory glutamatergic neurotransmission 
through a process involving astrocytic ATP release and P2 receptor activation 
(Koizumi et al., 2003). The same group showed that unstimulated astrocytes 
exhibit spontaneous Ca2+ waves which exert a tonic inhibition on glutamatergic 
neuronal transmission. This tonic inhibition was abolished by inhibiting 
astrocytic ATP release (Koizumi et al., 2003). The adaptive increase of 
breathing following pH changes in the brain is also mediated by Ca2+ wave 
propagation. Small pH changes in the brainstem causes an increase in [Ca2+]I 
and ATP release. This results in Ca2+ wave propagation across populations of 
astrocytes, and subsequent activation of chemoreceptor neurones (Gourine et 
al., 2010).  
 
As with general astrocytic ATP release, views regarding the mechanism behind 
Ca2+ wave propagation are opposing. Cotrina et al showed that Ca2+ wave 
propagation through stimulation of P2 receptors was a result of ATP release 
through hemichannels, acting on P2Y receptors. This was shown to also involve  
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Figure 1.4. Diagrammatic representation of the astrocytic calcium wave propagation. A. 
Extracellular ATP acts on purinergic receptors (P2R) on astrocytes. B. This causes an increase 
in intracellular calcium, which opens connexin hemmichanels (Cx), releasing ATP (C.). D. This 
ATP acts on neighbouring astrocytes to in turn increase intracellular calcium and  cause further 
ATP release, thus propagating the signal. 
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the activity of Cl- channels, and was not blocked by inhibiting P2X receptors or 
gap junctions (Cotrina et al., 1998). Another study showed that Ca2+ wave 
propagation was not through Cx43 hemichannels, but through the activation of 
P2X7 receptors, causing ATP-induced ATP release (Suadicani et al., 2006). 
Bowser and Khakh on the other hand showed that Ca2+ wave propagation 
caused by mechanical stimulation was mediated through vesicular ATP release 
acting on P2Y1 receptors (Bowser and Khakh, 2007). Even though the 
evidence on the ATP release mechanism is contradicting, most studies seem to 
agree that this eATP acts in P2Y receptors to propagate the signal.  
 
1.5.4   The purinergic system in diabetes 
 
Numerous studies have suggested alterations in the purinergic system in T1D 
and T2D patients as well as animal models of diabetes. These have been 
shown in a variety of tissues, and in most cases are believed to be a result of 
prolonged hyperglycaemia. For review see (Burnstock and Novak, 2013).  
 
ATP sensitivity was shown to increase in skin fibroblasts exposed to high 
glucose concentrations, and P2X7 receptors exhibited aggregation into ring-like 
structures in the periphery of the cells (Solini et al., 2000). In fibroblasts from 
T2D patients, there was an increase in P2X7 receptor-mediated responses and 
a large increase in extracellular ATP (Solini et al., 2004). P2X7 receptors were 
also upregulated in islets of obese patients, but downregulated in islets of T2D 
patients. This was thought to be due to the hyperglycaemia-protective release 
of interleukin-1 receptor agonist (IL-1Ra) by P2X7 receptors (Glas et al., 2009).  
P2X2 and 3 have also been shown to be altered in STZ-induced diabetic rats 
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and mice in the periphery, as have nucleotide release, uptake and sensitivity 
(Burnstock and Novak, 2013).  
 
In the brain, and more specifically in the hippocampus of STZ-induced diabetic 
rats, decreased ADORA1 and increased ADORA2A receptor expression has 
been reported. Duarte et al also observed a decrease in ATP metabolism and 
decrease in P2X3, 5, 7 and P2Y2, 6 and 11 receptor expression in nerve 
terminals of the hypothalamus of STZ rats. This was accompanied by an 
increase in P2X1, 2, 5, 6, 7 and P2Y6 receptors in whole hippocampal 
membranes and a decrease in cerebrospinal fluid ATP (Duarte et al., 2007). In 
microglia, exposure to high glucose concentrations resulted in an enhanced 
Ca2+ response to P2 receptor activation. Glucose starvation in astrocytes also 
showed mediations in the purinergic system, where an increase in P2Y4 was 
observed, coupled to a decrease in NMDAR1 (Cavaliere et al., 2004). 
 
High glucose also resulted in defective gap junctional communication and 
reduced expression of Cx36 and Cx30 in astrocytes in culture. The same 
effects were seen in brain slices of STZ diabetic rats, and this was shown to be 
through oxidative stress (Gandhi et al., 2010). Allard et al also showed changes 
in Cx43 expression in the mediobasal hypothalamus (MBH). Cx43 is highly 
expressed in the ARC and ventromedial hypothalamus (VMN), especially 
around capillaries and the edge of the medial part of 3V. Hyperglycaemia 
caused an increase in the expression in the MBH, and Cx43 inhibition in the 
MBH was shown to reduce the insulin response observed during central 
hyperglycaemia. On the other hand, fasting was shown to reduce Cx43 
expression which persisted following refeeding (Allard et al., 2014). These 
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studies suggest that connexin expression is dynamic, adapting to changes in 
metabolic demands, and that they might play an important role in the response 
to these metabolic challenges, potentially through changes in ATP release and 
thus purinergic signalling.  
 
The purinergic system is altered following high or low glucose exposure, as well 
as in diabetes and obesity. These changes in purinergic signalling are tissue 
specific and may underlie some of the pathologies in diabetes. 
 
1.6   Astrocytic lactate 
1.6.1   The astrocyte-neurone lactate shuttle (ANLS) hypothesis 
 
Glucose is thought of as the main energy source in the brain; however, 
neurones are also capable of metabolising lactate and ketones for energy. Both 
can be produced by astrocytes during periods of energy stress, such as 
hypoglycaemia (Pellerin and Magistretti, 2012; Taib et al., 2013). Some studies 
suggest that GE neurones might even preferentially use lactate over glucose 
(Beall et al., 2012b; Song and Routh, 2005).  
 
Lactate in the brain can either be transported across the blood-brain barrier via 
MCT or can be produced by astrocytes. Some studies have shown an increase 
in MCT expression at the blood-brain barrier and an increase in lactate import 
into the brain during hypoglycaemia following antecedent hypoglycaemia and in 
T1D patients (Herzog et al., 2013; Mason et al., 2006). This change in lactate 
transport, however, is not enough to support normal neuronal function, 
suggesting that another mechanism, such as locally derived lactate, may be 
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essential to maintain neuronal activity. Changes in neuronal metabolism have 
also been reported; indicating neurones may become more efficient at 
metabolising glucose. However, the increase in brain lactate appears to be 
necessary for the maintenance of normal neuronal function during 
hypoglycaemia (Herzog et al., 2013). 
 
A prevalent hypothesis is that during hypoglycaemia, astrocytes increase the 
production and export of lactate, providing neurones with energy during energy 
stress (Pellerin and Magistretti, 2012) (Figure 1.5).  During energy demand, 
astrocytic lactate is essential for maintenance of neuronal activity and survival 
(Brown et al., 2003; Suh et al., 2007; Swanson and Choi, 1993; Walls et al., 
2008). Astrocytes are highly glycolytic cells, with most glucose being 
metabolised anaerobically. Astrocytes express glucose transporters, 
predominantly GLUT1 (Iwabuchi et al., 2014), allowing glucose uptake. They 
also express hexokinase I, which phosphorylates glucose into glucose-6-
phosphate in the first step of glycolysis (Wiesinger et al., 1997). As mentioned 
previously (Chapter 1.4), astrocytes possess the necessary equipment for 
highly efficient lactate production and export.  Both astrocytes and neurones 
express GS, which allows glycogen synthesis, however, only astrocytes 
express GP which allows its subsequent breakdown. This is in agreement with 
the notion that astrocytes are the major glycogen stores in the brain (Wiesinger 
et al., 1997). The lactate produced, either by breakdown of blood-derived 
glucose, or breakdown of glycogen stores, can then be transported out of the 
astrocytes, into the extracellular space, and then into the neurones through 
MCT transporters, which are highly expressed in both astrocytes and neurones. 
This process, by which glucose or glycogen is metabolised into lactate and  
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Figure 1.5. The ANLS hypothesis. According to the ANLS hypothesis, glucose is taken up by 
astrocytes (blue) through Glut transporters. There it can be stored as glycogen or broken down 
to pyruvate. Pyruvate can then be converted to lactate through the action of LDH, and exported 
through MCT transporters. Lactate can then be taken up into neurones (green) through MCT 
transporters, and used as fuel. 
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exported out of astrocytes to provide neurones with energy is referred to as the 
astrocyte-neurone lactate shuttle (ANLS) hypothesis (Pellerin and Magistretti, 
1994).  
 
1.6.2   Brain glycogen supercompensation 
 
One adaptation of astrocytes to hypoglycaemia and ischemia which has been 
reported by multiple studies is glycogen supercompensation. Iwabuchi et al 
showed a decrease in astrocytic glycogen during mild ischemia, in vitro, 
followed by an increase to levels above basal during re-perfusion. They 
interpret this as one of the mechanisms behind ischemia pre-conditioning. The 
increase in glycogen storage following a mild ischemic insult would increase the 
capacity of astrocytes to produce lactate and thus prolong fuelling of neurones 
during a future, severe ischemic insult (Iwabuchi et al., 2014). This mechanism 
is thought to also be responsible for maladaptive responses of antecedent 
hypoglycaemia, leading to impaired CRR and hypoglycaemia unawareness. An 
adaptive increase in glycogen storage in astrocytes could support neuronal 
function during hypoglycaemia for prolonged periods, preventing neurones from 
detecting and responding to the hypoglycaemic episode. Studies have shown 
increases in brain lactate during hypoglycaemia, which cannot be explained by 
increases in lactate transport across the blood-brain barrier alone, and thus it is 
speculated that glycogen supercompensation in astrocytes may be resulting in 
increased lactate production and export during hypoglycaemia (Herzog et al., 
2013).  Glycogen supercompensation has been demonstrated by multiple 
groups in a variety of models. In mice, glycogen supercompensation was shown 
following acute or recurrent hypoglycaemia, demonstrating that even a single 
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bout of hypoglycaemia may be enough to induce changes in brain glycogen 
storage (Canada et al., 2011). In healthy human volunteers, an increase in 
glycogen mobilisation was reported during hyperinsulimic-hypoglycaemic 
clamp, compared to hyperinsulimic-euglycaemic clamp. This group further 
showed an increase in brain glycogen following hypoglycaemia that persisted 
for at least 80 hours (Oz et al., 2009).  
 
These studies would suggest that following antecedent hypoglycaemic episodes 
glycogen storage in astrocytes increases. This allows for prolonged lactate 
release following future hypoglycaemic events, which would prolong neuronal 
activity. In fact, studies have shown that an increased brain glycogen content 
prior to hypoglycaemia, preserves neuronal activity for longer during 
hypoglycaemia (Suh et al., 2007). This increase in lactate release by astrocytes 
however, may be preventing neurones from responding to hypoglycaemia and 
thus resulting in defective or delayed CRR. Neurones are able to use lactate as 
fuel, and some studies even suggest that neurones may have a preference in 
lactate metabolism. Lactate has a greater capacity to depolarise GE neurones 
in culture and in slices than glucose (Beall et al., 2012b; Song and Routh, 
2005). Furthermore, both GE and GI neurones have been shown to respond to 
lactate, which reverses low-glucose-induced KATP channel activation (Song and 
Routh, 2005).  
 
These studies all support the hypothesis that glycogen supercompensation may 
occur following RH. However there have been other studies which have failed to 
show changes in brain glycogen following RH. A study on rats by Herzog et al 
observed no changes in brain glycogen following acute or RH (Herzog et al., 
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2008). In a later study in humans by Oz et al, no glycogen supercompensation 
was seen in T1D and hypoglycaemia unawareness (Oz et al., 2012). Accurately 
measuring glycogen stores in the brain is difficult, as glycogen storage can be 
affected by a variety of conditions and drugs such as phenobarbital 
anaesthesia, which could explain the contradicting results in this case (Nelson 
et al., 1968). 
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Study aims 
 
This study aims to investigate the potential involvement of astrocytes in the 
central detection of hypoglycaemia. Provided that astrocytes respond to a 
hypoglycaemic stimulus, this study further aims to investigate whether 
astrocytes undergo adaptive responses following RH, which may underlie or 
contribute to the impaired CRR observed in diabetes. We hypothesise that in 
response to a hypoglycaemic stimulus, astrocytes will have an increase in 
AMPK activity. We further hypothesise that this AMPK activation may lead to 
changes in eATP. This would lead to changes in purinergic activation in 
neurones and astrocytes, as well as changes in astrocytic calcium wave 
propagation. Extracellular lactate would be expected to decrease during a 
hypoglycaemic stimulus, as less glucose would be available for glycolysis. We 
speculate that following RH, the AMPK, and as a result, the eATP response to a 
hypoglycaemic stimulus will be blunted, reflecting the blunted CRR response 
observed in diabetes following RH. Based on the glycogen supercompensation 
hypothesis (Canada et al., 2011; Iwabuchi et al., 2014), we speculate that 
extracellular lactate (eLactate) may not drop to the same extent during a 
hypoglycaemic stimulus following RH compared to control.  
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and equipment 
 
2-mercaptoethanol – Sigma Aldrich 
A769662 – Tocris 
AICAR – Tocris 
Ammonium persulfate (APS) – Sigma Aldrich 
ATPLite Luminescence assay system – Perkin Elmer 
BAPTA-AM – Abcam 
Benzamidine – Sigma Aldrich 
Bio-Rad Protein Assay Dye Reagent – BioRad 
BioTrace™ Nitrocellulose – VWR 
Bovine Serum Albumin (BSA) – Sigma Aldrich 
Bovine Serum Albumin Standard (2mg/ml) – Life Technologies 
Bromophenol Blue sodium salt (BPB) – Sigma Aldrich 
Carbenoxolone disodium – Tocris 
D-(+)-Glucose – Sigma Aldrich 
Dithiothreitol (DTT) – Melford 
DMEM, no glucose – Thermo Fisher 
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DMEM, no glucose, no phenol red – Thermo Fisher 
Dulbecco's Modified Eagle's Medium (DMEM), high glucose, without L-
glutamine, without Sodium Pyruvate – Sigma Aldrich 
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) – 
Melford 
Ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA) – Sigma 
Aldrich 
Fluo-4 Direct Calcium Assay reagent – Thermo Fisher 
Glycerol – Sigma Aldrich 
Glycine – Melford 
Grade 3MM Chr blotting paper – Fisher Scientific 
HBSS, without calcium-magnesium-phenol red – Thermo Fisher 
HEPES (1M) – Sigma Aldrich 
Hyclone Serum – GE Healthcare Bio 
Lactic acid (Lactate) – Sigma Aldrich 
L-Glutamine (200mM) – Thermo Fisher 
L-Lactic Dehydrogenase (LDH) from rabbit muscle – Sigma Aldrich 
Metformin – Abcam 
Methanol – Sigma Aldrich 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) – Sigma Aldrich 
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Noradrenaline – Abcam 
Penicillin-Streptomycin (5,000 U/ml) – Thermo Fisher 
Phenylmethanesulfonyl fluoride (PMSF) – Sigma Aldrich 
Phosphate Buffered Saline tablets (PBS) – Thermo Fisher 
Poly-L-lysine Hydrobromide – Sigma Aldrich 
Ponceau S solution – Sigma Aldrich 
ProtoGel (30%) Acrylamide – Fisher Scientific 
Quinacrine dihydrochloride – Sigma Aldrich 
SeeBlue Plus2 Pre-stained Protein Standard – Thermo Fisher 
Semicarbazide – Sigma Aldrich 
Sodium Chloride (NaCl) – Sigma Aldrich 
Sodium Dodecyl sulphate (SDS) – Melford 
Sodium Fluoride (NaF) – Sigma Aldrich 
Sodium Hydroxide – Sigma Aldrich 
Sodium Orthovanadate – Sigma Aldrich 
Sodium Pyrophosphate Tetrabasic Decahydrate (NaPPi) – Sigma Aldrich 
Sucrose – Melford 
Sulfuric Acid H2SO4 – Sigma Aldrich 
Tris(hydroxymethyl) aminomethane (TRIS) – Melford 
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TritonX-100 – VWR 
Trypsin (2.5%), no phenol red – Thermo Fisher 
Trypsin-EDTA (0.05%), phenol red – Thermo Fisher 
TWEEN 20 – Sigma Aldrich 
β-Nicotinamide adenine dinucleotide sodium salt (NAD) – Sigma Aldrich 
 
2.1.2 Antibodies 
 
ACTB Mouse Monoclonal – Protein Tech (60008-1-Ig) 
Goat Polyclonal anti-rabbit – Rockland (ROCK611-132-122) 
Donkey anti-sheep – Life Technologies (A21102) 
Goat anti-mouse – Life Technologies (A21057) 
pT172 AMPK – Cell Signalling (2535L) 
pS15 Glycogen phosphorylase – DSTT 
pS79 Acetyl CoA carboxylase (ACC) – Cell Signalling (3661S) 
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2.2 Methods 
2.2.1 Cell culture 
 
 
2.2.1.1 Neonatal primary astrocyte isolation and culturing 
 
T75 flasks were coated with 10 µg/ml Poly-L-lysine (PLL) and incubated for 1 
hour before washing with PBS. Primary astrocyte cultures were prepared from 
mice at P1-5. The mice were decapitated, and the skull opened using a scalpel. 
The meninges were removed and the cortices and hypothalamus were 
dissected from the brain tissue and minced separately in HBSS. The cortices 
and hypothalamus were then transferred to 5ml trypsin-EDTA (0.5% w/v) and 
incubated at 37oC for 20min, shaking every 5min. The tissue was then 
centrifuged at 1,000rpm for 5min. Excess trypsin was removed and the tissue 
re-dissolved in 25mM glucose stock media, with 10% (v/v) serum before 
transferring through a cell strainer into the PLL-coated flasks. The cells were 
Table 1: Media compositions 
Media Components 
Stock media High glucose (25 mM) DMEM, 10% (v/v) Hyclone serum, 
2% (v/v) Pen/Strep, 4% (v/v) L-glutamine 
Experimental media Glucose-free DMEM (11966), 10% (v/v) Hyclone serum, 
2% (v/v) Pen/Strep, 2% (v/v) L-glutamine, 2.5-7.5 mM 
glucose 
Serum free (SF) media Glucose-free DMEM (11966), 0.1-10 mM glucose 
Phenol red-free serum-
free (PrF/SF) media 
Glucose-free, phenol red free DMEM, 2.5 mM Glucose, 
25 mM HEPES 
Normal saline 135 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 10 
mM HEPES, 2.5 mM glucose 
Calcium-free saline 135 mM NaCl, 5 mM KCl, 1 mM MgCl2, 3 mM Mannitol, 
10 mM HEPES, 2.5 mM glucose 
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cultured in 25mM stock media, replacing the media every 2-3 days until ready to 
plate for experiments. 
 
2.2.1.2 Culturing of U373 MG cells 
 
Cells were cultured in T75 or T175 flasks in 15 or 25ml of 25mM glucose stock 
media respectively, passaging them every 3-4 days up to no more than p35.  
 
2.2.1.3 Plating cells for experiments 
 
For experiments, cells were plated in 2.5-7.5mM glucose DMEM 1-2 days 
before experimentation. For primary astrocyte cultures, the dishes or plates 
were coated with PLL prior to plating. To delay cell attachment and promote a 
more even cell distribution, the cells were left in the hood for 30-60 minutes 
before placing in the incubator. Before experiments, the cells were serum 
starved using 2.5mM glucose serum free (SF) media for 2hr. 
 
2.2.1.4 Collection of supernatants and protein extraction 
 
At the end of treatment, media samples were collected from each dish, 
transferred to microtubes and kept on ice. These samples were used for 
extracellular assays or stored at -20oC for further analysis. The cells were lysed 
using lysis buffer and scraped on ice. The cell lysates were collected into 
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microtubes and centrifuged at 14,000rpm at 4oC for 15min. Protein 
concentration was determined by the method of Bradford (Bradford, 1976) and 
retained for Western blotting analysis. 
 
5 x Lysis Buffer: 
125 mM Tris HCl (pH 7.5) 
250 mM NaF 
0.5 M NaCl 
5 mM EDTA 
25 mM EGTA 
5% (v/v) Triton X 100 
50 mM NaPPi 
 
Added fresh on the day to 1 x Lysis buffer: 
92 mg/mL Sucrose 
1 mM PMSF 
1 mM Benzamidine 
1 mM Sodium Orthovanadate 
0.1% (v/v) 2-Mercaptoethanol 
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Table 2: Plate seeding protocol 
 Plated one day before experiment Plated two days before 
experiment 
 U373 Primary astrocytes U373 Primary 
astrocytes 
96-well 
plate 
20,000 cells 20,000 cells N/A N/A 
4cm dish 
(glass-
bottomed) 
N/A N/A 80,000 cells 80,000 
cells 
6-well 
plate 
150,000 cells 150,000 cells N/A N/A 
6cm dish 450,000 cells 450,000 cells 300,000 cells 450,000 
cells 
10cm dish 1,000,000 cells N/A N/A N/A 
 
2.2.1.5 Recurrent Hypoglycaemia 
 
U373 cells were plated at 200,000 cells per dish in twelve 6cm dishes the day 
before experimentation in 7.5mM glucose media with serum. On day one, the 
cells were serum starved in 3ml 2.5 mM glucose serum free media for 2 hours 
followed by 2 hours of 0.1mM or 2.5mM glucose in 3ml serum free media for the 
hypoglycemic vs euglycemic stimulus. The cells were then recovered in 3ml 
5mM glucose serum free media for 2 hours before repeating the hypoglycemic 
vs euglycaemic stimulation for two hours. The cells were then recovered 
overnight in 5ml 5mM glucose serum free media. The same procedure was 
repeated on day two, omitting the first 2 hour serum starving step. After the first 
recovery, the cells were split into three sets of four containing two dishes that 
had been exposed to RH and two that had not. Each pair from these was  
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exposed to 2.5 or 0.1mM glucose for 15, 30, or 180 minutes before collecting 
the media and lysate samples (see Figure 2.1).  
 
2.2.2 Determining protein concentration 
 
0-5µl of 1mg/mL BSA standard was used in triplicates in a clear 96-well plate for 
the protein standards, adding 1l of the lysis buffer to each. 1µl of the sample 
lysates was added/well in triplicates and 200µl of Bradford reagent was added 
to each well. The plate was shaken for 5 minutes before reading at 595nm. 
 
2.2.3 Immunoblotting 
 
The cell lysates were prepared in sample buffer (see table 3) containing DTT 
(100mM) or β-Mercaptoethanol (0.1% v/v). 10µg of lysate was loaded per well 
and run initially at 90-100mV for 15-20 minutes to ensure optimal protein 
migration, and then at 150mV for a further ~90 minutes to separate the proteins. 
The proteins were transferred onto Nitrocellulose membranes using a wet 
transfer, and transferred at 100mV for 75min. The membranes were then 
blocked in 5-10% (w/v) dried skimmed milk, or 1-2.5% (w/v) BSA (made up in 1-
2.5% w/v BSA in TBS/TWEEN) for 1 hour and placed in primary antibody (made 
up in 1-2.5% w/v BSA in TBS/TWEEN) overnight (see table 5). The primary 
antibody was then removed and the membranes washed 6 times in 
TBS/TWEEN changing the wash every 5-10 minutes before placing in the 
secondary antibody (made up in 1-2.5% w/v BSA in TBS/TWEEN) for 60min.  
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The membranes were then washed 6 times in TBS/TWEEN changing the wash 
every 10 minutes and scanned using the Licor Odyssey CLx. 
 
Table 3: Western blot buffer components 
Buffer Recipe 
4x Sample Buffer 125 mM Tris/HCl (pH 6.8), 4% (w/v) SDS, 20% (v/v) 
Glycerol, BPB, made up in dH2O 
Transfer buffer 20% (v/v) Methanol, 0.048 M Tris, 0.039 M Glycine, made 
up in dH2O 
10x Running buffer 0.25 M Tris, 1.92M Glycine, 1% (w/v) SDS 
TBS/TWEEN 152 mM NaCl, 20 mM TRIS/HCl (pH 7.4), 0.05% (v/v) 
TWEEN 20 made up in dH2O 
 
 
Table 4: Gel-making protocol 
2 x Gels Stacking (4%) 7% 10% 
d.H2O 2.8 ml 5.28 ml 4.15 ml 
1.5 M Tris (pH 8.8)  3.15 ml 3.15 ml 
0.5 M Tris (pH 6.8) 1.25 ml   
30% Acrylamide 850 µl 2.63 ml 3.75 ml 
10% (w/v) SDS 50 µl 110 µl 110 µl 
20% (w/v) APS 50 µl 55.4 µl 55.4 µl 
TEMED 5.35 μl 11 µl 11 µl 
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Table 5: Antibody dilutions and incubation conditions 
Antibody Dilution Incubation 2ary antibody Dilution Incubation 
pT172 AMPK 1:1,000 Overnight 
Cold room 
Anti-Rabbit 1:10,000 1hr RT 
pS79 ACC 1:1,000 Overnight 
Cold room 
β-Actin 1:5,000 Overnight 
Cold room 
pS15 Glycogen 
phosphorylase 
1 µg/ml Overnight 
Cold room 
Anti-Sheep 1:5,000 1hr RT 
ACTB Mouse 
Monoclonal  
1:10,000 1hr RT Anti-Mouse 1:10,000 1hr RT 
 
2.2.4 ATP assay 
 
For determining extracellular, intracellular or total ATP concentration, the 
ATPlite assay kit was used as described below. 
 
2.2.4.1 Determining extracellular ATP concentration 
 
For determining extracellular ATP concentration 80µl of conditioned media 
(CM), 40µl Mammalian Cell Lysis Solution, and 40µl reconstituted ATP 
Substrate Solution were used in triplicates in a black 96-well plate. The 
standard curve was prepared in triplicates in 80μl of the media used during the 
treatment. 
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2.2.4.2 Determining intracellular ATP concentration 
 
For determining intracellular ATP concentration, cells were plated in a black 96-
well plate and treated in triplicates. At the end of the treatment the media was 
aspirated and 40μl Mammalian Cell Lysis Solution and 80μl of the media used 
to treat the cells was added to the wells. 40μl reconstituted ATP Substrate 
Solution was used for this reaction. 
 
2.2.4.3 Determining total ATP concentration 
 
For determining total ATP concentration, cells were plated in a black 96-well 
plate and treated in 100μl of the treatment media in triplicates. At the end of 
treatment 50μl Mammalian Cell Lysis Solution was added to the wells. 50μl of 
reconstituted Substrate Solution was used for this procedure.  
 
2.2.5 Determining extracellular lactate concentration 
 
For determining extracellular lactate concentration an assay based on the 
reaction below was used, measuring changes in absorbance from the 
production of NADH: 
         
                                            
 
Pyruvate + NADH 
LDH 
Lactate + NAD+ 
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The lactate assay reaction buffer was prepared as shown below: 
Reaction Buffer pH 10 (100ml in dH2O): 
1.5g Glycine 
2.23g Semicarbazide  
Added fresh on the day (for 10ml): 
0.02152mg NAD 
50µl LDH 
The following reaction was prepared in a clear 96-well plate (see table 6), 
incubated at 37oC for 1 hour shaking every 10 minutes for 5 minutes and the 
absorbance read at 350/450: 
Table 6: Plate setup for extracellular lactate assay 
 Lactate Media CM Reaction Buffer 
0 nmol 
Standard 
10µl of 0mM 90μl - 100µl 
10 nmol 
Standard 
10µl of 1mM 90μl - 100µl 
20 nmol 
Standard 
10µl of 2mM 90μl - 100µl 
30 nmol 
Standard 
10µl of 3mM 90μl - 100µl 
40 nmol 
Standard 
10µl of 4mM 90μl - 100µl 
50 nmol 
Standard 
10µl of 5mM 90μl - 100µl 
Samples - - 100µl 100µl 
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2.2.6 Intracellular Ca2+ assay 
 
Cells were plated in a quarter of a clear 96-well plate in 7.5mM glucose 
experimental media as described above. After serum starving for 2hr, the media 
was replaced with Fluo 4 direct calcium dye made up in phenol red-free DMEM 
(25mMHEPES, 2.5mM glucose) and incubated for 1 hour at 37oC before 
reading in the PheraStar. Treatment was injected at t=30s. Each treatment 
group was done in triplicate or quadruplicate. Relative fluorescence was 
calculating by dividing each value by the baseline reading (t=0s) of the 
corresponding well and then calculating the mean of the triplicates or 
quadruplicates for each treatment group at each time point measured. The total 
area under the curve for each treatment group was calculated setting the 
baseline to 1. 
 
2.2.7 Quinacrine Imaging 
 
Protocol 1 
80,000 cells or 100,000 cells of U373 or mouse primary astrocytes respectively 
were plated per 4cm glass-bottomed dishes two days before imaging in 25mM 
glucose stock media. The day before the experiment the media was replaced 
with 7.5mM glucose experimental media. The cells were serum starved in 
2.5mM SF media for 2hr, before loading with 1µM Quinacrine made up in 
2.5mM glucose 25mM HEPES buffered PrF/SF media for 15 minutes at room 
temperature. The dye was washed off and the cells incubated at 37oC in 750µl 
2.5mM glucose 25mM HEPES buffered PrF/SF media for 15min. The cells were 
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imaged using a confocal microscope, capturing one image per minute. At 
t=10min, 750µl of treatment were added. 
Protocol 2 
The procedure above was used, using 1.4ml media after washing off the 
quinacrine, and 100µl for treatment instead, to minimise shear stress on the 
cells. 
 
2.3 Statistical analysis 
 
All data-sets are shown as mean with standard error unless otherwise stated. 
Values for western blots were normalised to actin and then to control, and were 
analysed using a one sample t-test unless otherwise stated. All other data-sets 
were analysed using a 1-way ANOVA or 2-way ANOVA with Bonferroni’s 
Multiple Comparison test. Significance is measured against control, unless 
stated otherwise, and is indicated as follows:  
* p≤0.05, ** p≤0.01, ***p≤0.001 
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Chapter 3: Results 
3.1   Hypoglycaemia detection in astrocytes 
Introduction 
 
Hypoglycaemia has been a known side-effect of insulin treatment for nearly a 
century (Banting et al., 1923); however, no effective preventative medication 
has yet been developed. There has been a multitude of studies showing the 
involvement of the central nervous system in glucosensing and the CRR to 
hypoglycaemia (Beall et al., 2012a) but the exact mechanism behind impaired 
CRR is still not fully understood. One enzyme that has been shown to play an 
important part in the response to hypoglycaemia and glucose regulation is 
AMP-activated protein kinase (AMPK).  
 
Activation of AMPK in the VMH was found to result in an increase in glucose 
production during hypoglycaemia (McCrimmon et al., 2006). The hypothalamus 
is a key regulator of whole body homeostasis, and is largely involved in the 
central response to changes in glucose (Allard et al., 2013; Guillod-Maximin et 
al., 2004). Specialised glucosensing neurons, found both peripherally and 
centrally, are highly expressed in the hypothalamus. Both glucose-excited and 
glucose-inhibited neurones are expressed, which respond to changes in 
glucose (Oomura et al., 1969). Increasing amounts of evidence implicate 
astrocytes in central glucosensing and the response to both hyper and 
hypoglycaemia (Lam et al., 2005; Marty et al., 2005; Taib et al., 2013).  
 
Guillod-Maximin et al showed that carotid artery glucose injection increases 
astrocyte activation in both the paraventricular nucleus (PVN) and ARC of the 
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hypothalamus. They further showed that inhibiting astrocytes in the ARC 
supressed the glucose-induced insulin secretion (Guillod-Maximin et al., 2004). 
Similarly, Allard et al showed that injection of glucose into the carotid artery 
stimulated the hypothalamo-pancreatic axis through a process requiring the 
conversion of glucose to lactate as well as pyruvate metabolism, suggesting the 
involvement of astrocytes (Allard et al., 2013). Astrocytes also play a crucial role 
in the response to hypoglycaemia. For example, Marty et al showed that 
inactivating the GLUT2 gene impaired the glucagon response to 
hypoglycaemia, which was restored when GLUT2 was re-expressed specifically 
in astrocytes (Marty et al., 2005). 
 
Astrocytes release a variety of gliotransmitters that can modulate neuronal 
activity. One of the gliotransmitters that has been implicated in diabetes is ATP. 
ATP is the universal “danger signal” and acts as a pro-inflammatory mediator 
(Idzko et al., 2014). It also acts as a fast excitatory neurotransmitter, mediating 
short-term as well as long-term effects. Changes in the purinergic system in the 
hippocampus of STZ rats have been observed, including changes in purinergic 
receptor expression, ATP metabolism and levels of extracellular ATP (Duarte et 
al., 2007). Fasting or hyperglycaemia also result in changes in astrocytic 
connexin expression (Allard et al., 2014; Gandhi et al., 2010) which is a 
membrane channel permeable to small molecules such as ATP. Based on 
these observations, we hypothesised that changes in extracellular ATP could 
play a part in the central regulation of glucose homeostasis and the adaptations 
following repeated episodes of hypoglycaemia. 
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Another astrocyte-derived gliotransmitter that plays an important part in a 
variety of neuronal pathways is lactate. Astrocytes can produce lactate from 
glucose taken up from the blood, or from glycogen stores, and provide it to 
neurones during energy stress as described by the astrocyte-neuron lactate 
hypothesis (Pellerin and Magistretti, 1994). There is strong evidence that lactate 
plays an important role in ischaemia pre-conditioning and the counter-regulatory 
response to hypoglycaemia.  For example, during ischemia pre-conditioning, 
Iwabuchi et al showed that brain glycogen content fell, followed by a further 
increase after re-perfusion, referred to as glycogen supercompensation 
(Iwabuchi et al., 2014). This increase in glycogen storage in astrocytes may be 
part of the mechanism behind the protective ability of ischemia pre-conditioning 
to further ischemic insult. Increasing glycogen stores enables astrocytes to 
provide neurones with lactate for a longer period of time and improve viability 
during glucose depletion. An increase in brain glycogen content in mice 
(Canada et al., 2011), rats (Choi et al., 2003) and humans (Oz et al., 2009) 
following acute or recurrent hypoglycaemia has also been shown, suggesting 
an adaptive mechanism to protect against future hypoglycaemic insults. In 
support of this, Suh et al showed a prolonged maintenance in neuronal activity 
during hypoglycaemia in rats with higher brain glycogen content at the start of 
hypoglycaemia (Suh et al., 2007). Lactate administration in the hypothalamus 
blunts the response to hypoglycaemia in rats (Borg et al., 2003). Taken 
together, these data suggest that an adaptive increased lactate release during 
hypoglycaemia may be responsible for the blunted counter regulatory response 
following recurrent hypoglycaemia. 
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The aim of this study was to characterise astrocytic response to a 
hypoglycaemic stimulus, and any potential adaptations following repeated 
hypoglycaemic stimuli. 
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3.1.1   Acute hypoglycaemia increases AMPK and ACC phosphorylation 
and decreases extracellular lactate in astrocytes 
 
To determine whether astrocytes detect and respond to hypoglycaemia, U373 
cells were exposed to physiological (2.5mM) or low (0.1mM) glucose levels for 
30 minutes. In vivo astrocytes remain in distinctly separate areas from each 
other, with very little overlap of processes (Bushong et al., 2002), however, they 
would also be receiving input from other cell types in their surrounding 
environment (Gundersen et al., 2015). To ensure we observe any significant 
differences caused by too much or too little interaction between our cells, this 
experiment was carried out at three different seeding densities (SD); low 
(150,000 cells/dish), medium (450,000 cells/dish) and high (1,000,000 
cells/dish), plated in round, 6 cm dishes the day before the experiment. AMPK 
phosphorylation was measured through densitometric analysis of Western blots 
as an indicator of AMPK activation. Acetyl co-A carboxylase (ACC) 
phosphorylation was also measured using the same method. ACC is a 
downstream target of AMPK, and thus changes in its phosphorylation serve as 
indications of changes in AMPK activity. Extracellular ATP (eATP) from the CM 
was measured using a luminescence, plate-based assay, and eLactate was 
measured using an enzymatic, absorbance, plate-based assay, to determine 
whether astrocytic function was altered during an acute hypoglycaemic 
stimulus. 
 
A significant increase in pAMPK was observed following low glucose in all SD 
groups (1.6, 2.4 and 2.9-fold in the low, medium and high respectively; Figure 
3.1A, B; n=5; p<0.01). A significant increase in phospho ACC (pACC) was also 
observed (2.4, 2.9 and 3.3-fold in the low, medium and high SD groups 
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respectively; Figure 3.1A, C; n=5; p<0.001). There was no significant change in 
absolute eATP during low glucose in any of the groups; However, when 
normalised to protein content, there was a significant decrease in eATP 
between the three SD groups at euglycaemic glucose, with eATP being 2 and 6 
times lower in the medium and high SD groups, respectively, when compared to 
the low SD group (Figure 3.1D, E; n=5; p<0.001). A 1.6-fold decrease in 
eLactate from 153.4 ± 18.28 to 95.78 ± 15.39 nmol/mg was measured in the 
high SD group following low glucose (Figure 3.1F; p<0.05; unpaired t test). In 
order to observe whether the decrease in eLactate was a direct result of 
decreased glucose availability for lactate production, eLactate, in this instance, 
was normalised to glucose availability. After normalising eLactate to glucose 
availability we see a 29.2, 21.2 and 15.6-fold increase in eLactate/mol of 
glucose available during a hypoglycaemic stimulus (Figure 3.1G; n=5; p<0.001; 
unpaired t test). 
 
These data indicate that the U373 cells detect and respond to a hypoglycaemic 
stimulus, seen through changes in AMPK activity. The hypoglycaemic stimulus 
also caused a decrease in eLactate, which was not proportional to the decrease 
in glucose availability, and thus indicates an increased efficiency in lactate 
production and export per mol of glucose available. Increasing cell SD was 
shown to result in an unexpected decrease in eATP, which may be a result of 
increased eATPase activity. This means astrocytic eATP cannot be normalised 
to protein content in the rest of this work. 
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Figure 3.1. Low glucose increases pAMPK, pACC and lactate production. A. 
Representative Western blots of U373 lysates of phospho-AMPK and phospho-ACC following 
30min of a euglucaemic (2.5mM) or hypoglycaemic (0.1mM) stimulus. B. Fold change in AMPK 
phosphorylation in U373 lysates (n=5). C. Fold change in ACC phosphorylation in U373 lysates 
(n=5). D. Extracellular ATP following treatment in U373 cells (n=5). E. Extracellular ATP 
normalised to protein content (n=5). F. Extracellular lactate following treatment in U373 cells 
(n=5). G. Extracellular lactate normalised to glucose concentration (n=5). B-D. & F-G. 2-way 
ANOVA with Bonferroni's multiple comparison test. E. 1-way ANOVA with Boneferroni's 
multiple comparison test. * p≤0.05, ** p≤0.01, *** p≤0.001 
 
  
  
73 
 
3.1.2   Noradrenaline increased extracellular lactate in both euglycaemic 
and hypoglycaemic conditions 
 
During hypoglycaemia, noradrenaline (NA) is released into hypothalamic areas 
by the hindbrain (Palkovits et al., 1980). To test whether the U373 response to 
low glucose is enhanced by NA, cells were plated at 450,000 cells/dish in 
round, 6 cm dishes the day before the experiment, and were exposed to a 30 
minute hypoglycaemic stimulus with or without the addition of NA (50µM). There 
was a significant increase in pAMPK in cells exposed to low glucose (2.0-fold ± 
0.2) when compared to the euglycaemic group (p<0.01). An increase in AMPK 
phosphorylation was also observed in U373 cells exposed to a hypoglycaemic 
stimulus +NA compared to euglycaemic conditions +NA, but did not reach 
significance. There was no significant change in pAMPK when comparing the 
vehicle-treated or NA-treated groups in either euglycaemic or hypoglycaemic 
conditions (Figure 3.2B; n=5). As observed previously (Figure 3.1A), there was 
also a significant increase in pACC in the vehicle-treated group in low glucose 
when compared to the control group (2.8-fold ± 0.4; p<0.01). A similar increase 
was observed in the NA-treated group when comparing the low glucose group 
to the euglycaemic group (2.1-fold ± 0.2; p<0.05). There was no significant 
difference in pACC between the vehicle-treated and NA-treated groups in either 
euglycaemic or hypoglycaemic conditions (Figure 3.2C; n=5). There was no 
significant difference in phospho-GP (pGP) or eATP between any of the groups 
(Figure 3.2D&E). There was a significant increase in eLactate from 178.8 ± 
21.09 nmol/mg in the vehicle-treated group, to 342.4 ± 32.09 nmol/mg in the 
NA-treated group in euglycaemic conditions and from 107.2 ± 11.85 nmol/mg in 
the control group, to 308.2 ± 49.87 nmol/mg in the NA-treated group in 
hypoglycaemic conditions (Figure 3.2F; n=6; p<0.01).  
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Figure 3.2. NA enhances lactate production during hypoglycaemic stimulus. A. 
Representative Western blots of pAMPK, pACC, pGP and Actin of lysates of U373 cells treated 
with noradrenaline (50µM) for 30min at 2.5 or 0.1mM glucose. B. Fold change in AMPK 
phosphorylation at the end of the 30min treatment (n=5). C. Fold change in ACC 
phosphorylation at the end of the 30min treatment (n=5). D. Fold change in GP 
phosphorylation at the end of the 30min treatment (n=5).  E. Extracellular ATP at the end of the 
30min treatment (n=6). F. Extracellular lactate at the end of the 30min treatment (n=6). B-F. 2-
way ANOVA with Bonferroni's multiple comparison test. * p≤0.05, ** p≤0.01, *** p≤0.001 
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NA had no effect on AMPK, ACC or GP phosphorylation or eATP on either 
euglycaemic or hypoglycaemic conditions. However, there was a nearly 2-fold 
increase in eLactate in normal glucose, and nearly 3-fold increase in low 
glucose when the cells were treated with NA. This increase in eLactate 
suggests that even though glycogenolysis appears to be increased during 
hypoglycaemia, it retains capacity to be further activated by NA. 
 
3.1.3   2-day antecedent hypoglycaemia blunts the AMPK response to 
further hypoglycaemia 
 
To investigate potential adaptive changes in astrocytes following recurrent 
episodes of hypoglycaemia, astrocytes were exposed to a 2-day recurrent 
hypoglycaemia model (Figure 2.1). U373 cells were plated the day before the 
start of the experiment at 250,000 cells/dish, in round 6 cm dishes. In this study, 
changes in AMPK and ACC phosphorylation were measured as well as 
changes in eATP. Changes in pGP and eLactate were also measured to 
investigate any changes in glycogenolysis. The results are shown as fold 
change from the 2.5mM glucose control for each group with standard error. The 
acute hypoglycaemia group (H) was normalised to the control group (C), and 
the recurrent hypoglycaemia group (RH) to the antecedent hypoglycaemia 
group (AH).  
 
In lysates of U373 cells exposed to the 2-day recurrent hypoglycaemia model, 
pAMPK after a 15 minute hypoglycaemic stimulus (0.1mM glucose) increased 
2.0-fold ± 0.3 in the H group and 1.4-fold (± 0.1) in the RH group compared to 
their corresponding control (2.5mM glucose; p<0.01). This was significantly 
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different between the two groups (0.6-fold ± 0.3; Figure 3.3.1B; n=7; p<0.05). 
ACC phosphorylation increased 1.9-fold ± 0.2 in the H group and 1.6-fold ± 0.1 
in the RH, which was not significant between groups (Figure 3.3.1C; n=9; 
p<0.01). Glycogen phosphorylase phosphorylation did not significantly change 
(Figure 3.3.1D), neither did eATP (Figure 3.3.1E) or eLactate (Figure 3.3.1F). 
 
Following a 30 minute hypoglycaemic stimulus, pAMPK remained elevated at 
1.9-fold ± 0.2 in the H group and 1.5-fold ± 0.2 in the RH group which was not 
significantly different between groups (Figure 3.3.2B; n=7; p<0.05). ACC 
phosphorylation was significantly increased to 2.9 ± 0.4 in the H group, and 3.5 
± 0.4 in the RH group which was not significant between groups (Figure 3.3.2C; 
n=9; p<0.01). There was no significant change in pGP for either group (Figure 
3.3.2D). eATP did not change significantly when comparing H or RH to their 
respective controls (C and AH). However, the response in the H group was 
significantly higher than in the RH (0.4 ± 0.2; Figure 3.3.2E; n=8; p<0.05). 
Extracellular lactate was significantly reduced in the RH group to 0.8-fold ± 0.03 
compared to its control (Figure 3.3.2F; n=7; p<0.001). 
 
Following a 180 minute hypoglycaemic stimulus, pAMPK was significantly 
increased to 2.6-fold ± 0.3 and 2.1-fold ± 0.1 in the H and RH groups 
respectively (Figure 3.3.3B; n=6; p<0.01). ACC phosphorylation was 
significantly increased to 6.7-fold ± 1.0 and 6.8-fold ± 1.0 in the H and RH 
groups respectively (Figure 3.3.3C; n=9; p<0.01). GP phosphorylation was also 
significantly increased to 1.6-fold ± 0.1 and 1.6-fold ± 0.2 in the H and RH 
groups (Figure 3.3.3D; n=6; p<0.05). Extracellular ATP did not significantly  
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Figure 3.3.1. Recurrent hypoglycaemia blunts the pAMPK response to further 
hypoglycaemia at 15min. A. Representative Western blots of pAMPK, pACC, pGP and Actin 
of lysates of U373 cells exposed to three 2hr bouts of euglycaemia or hypoglycaemia over two 
days, followed by 15min of euglycaemia (2.5mM glucose) or hypoglycaemia (0.1mM glucose). 
B. Fold change in AMPK phosphorylation (n=7). C. Fold change in ACC phosphorylation (n=9). 
D. Fold change in GP phosphorylation (n=7). E. Extracellular ATP at the end of the final 15min 
hypoglycaemic stimulus (n=8). F. Extracellular lactate at the end of the final 15min 
hypoglycaemic stimulus (n=8). B-F. * p≤0.05 Comparing H to RH using an unpaired t test. ## 
p≤0.01, ### p≤0.001 Comparing each group to their corresponding control to which they have 
been normalised, using a one sample t test (hypothetical value of 1). 
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Figure 3.3.2. Recurrent hypoglycaemia blunts the pAMPK response to further 
hypoglycaemia at 30min. A. Representative Western blots of pAMPK, pACC, pGP and Actin 
of lysates of U373 cells exposed to three 2hr bouts of euglycaemia or hypoglycaemia over two 
days, followed by 30min of euglycaemia (2.5mM glucose) or hypoglycaemia (0.1mM glucose). 
B. Fold change in AMPK phosphorylation (n=7). C. Fold change in ACC phosphorylation (n=9). 
D. Fold change in GP phosphorylation (n=7). E. Extracellular ATP at the end of the final 30min 
hypoglycaemic stimulus (n=8). F. Extracellular lactate at the end of the final 30min 
hypoglycaemic stimulus (n=7). B-F. * p≤0.05 Comparing H to RH using an unpaired t test. # 
p≤0.05, ## p≤0.01, ### p≤0.001 Comparing each group to their corresponding control to which 
they have been normalised, using a one sample t test (hypothetical value of 1). 
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Figure 3.3.3. Recurrent hypoglycaemia blunts the pAMPK response to further 
hypoglycaemia at 180min. A. Representative Western blots of pAMPK, pACC, pGP and Actin 
of lysates of U373 cells exposed to three 2hr bouts of euglycaemia or hypoglycaemia over two 
days, followed by 180min of euglycaemia (2.5mM glucose) or hypoglycaemia (0.1mM glucose). 
B. Fold change in AMPK phosphorylation (n=6). C. Fold change in ACC phosphorylation (n=9). 
D. Fold change GP phosphorylation (n=6). E. Extracellular ATP at the end of the final 180min 
hypoglycaemic stimulus (n=7). F. Extracellular lactate at the end of the final 180min 
hypoglycaemic stimulus (n=8). B-F. # p≤0.05, ## p≤0.01, ### p≤0.001 Comparing each group 
to their corresponding control to which they have been normalised, using a one sample t test 
(hypothetical value of 1). 
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change in either group (Figure 3.3.3E). Extracellular lactate was significantly 
decreased to 0.4-fold ± 0.03 in the H group and 0.5-fold ± 0.02 in the RH group 
(Figure 3.3.3F; n=8; p<0.001).  
 
No significant difference in basal (C vs AH) pAMPK, pACC, pGP, eATP or 
eLactate was observed (see Supplementary figures S2-S3 for a representation 
of the data from Figure 3.3.1-3.3.3 before normalising the H and RH groups to 
their respective controls). 
 
In the U373 cells there was a blunted AMPK activation at the earlier time points 
following RH, demonstrated by the attenuated increase in AMPK 
phosphorylation in the RH group compared to the H at 15 min, which stayed 
persistently although not significantly lower in the 30 and 180 min timepoints. 
This, however, did not translate to reduced ACC phosphorylation, as there was 
no significant difference between the two groups. There was a lowered eATP 
response in the RH group compared to H which was only significant at 30min. 
The reduction in eLactate appeared to occur more rapidly following RH, which 
would suggest a faster activation of glycogenolysis in these cells. 
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3.2   Discussion 
 
In our study, a hypoglycaemic stimulus induced an increase in pAMPK in U373 
cells plated at different seeding densities (Supplementary figure S1). This 
increase in AMPK activation indicates that U373 astrocytoma cells detect and 
respond to a hypoglycaemic stimulus. It has previously been demonstrated that 
stressful stimuli, including hypoglycaemia, cause an increase in AMPK activity 
through changes in cytosolic AMP/ATP ratio in a variety tissues and cell-types. 
Hypoglycaemia in our study also resulted in an increase in ACC 
phosphorylation, a downstream target of AMPK, indicating an increase in AMPK 
activity (Figure 3.1A-D).  
 
No change in eATP was observed during acute hypoglycaemic stimulus. 
However, there was a significant decrease in eATP as seeding density 
increased (Figure 3.1E). This effect of cell density on eATP may be due to 
increased ATP breakdown by eATPases. As seeding density increases, cells 
are at closer proximity to each other, which is likely to increase ATP breakdown 
by eATPases.  Astrocytes, as well as most cell types express eATPases, 
especially NTPDase2, which preferentially hydrolyses ATP (Wink et al., 2006). 
These act to break down ATP to its constituents, such as AMP, ADP and 
adenosine. This is an important step in purinergic signalling, terminating 
transmission and allowing the uptake and recycling of nucleotides 
(Zimmermann et al., 2012). 
 
The acute hypoglycaemic stimulus also caused an increase in lactate 
production compared to glucose availability. This suggests that during energy 
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stress, astrocytes may be working to maintain energy supply to adjacent 
neurones. This is in agreement with studies showing that astrocytes are able to 
prolong neuronal viability and activity during energy starvation by producing and 
exporting lactate (Brown et al., 2003; Suh et al., 2007; Swanson and Choi, 
1993). Astrocytes are highly glycolytic cells, optimised for lactate production and 
export (Walz and Mukerji, 1988). They express high levels of LDH1 and 5, of 
which LDH5 has a higher affinity for pyruvate than lactate, thus favouring lactate 
production (Laughton et al., 2007). Astrocytes also express MCT, particularly 
MCT1 and 4, which allow the export of lactate from the cells (Pellerin et al., 
2005). Lactate can be produced through two main processes in astrocytes, 
glycolysis where blood-derived glucose is hydrolysed to lactate or 
glycogenolysis, where glycogen stores are broken down. Astrocytes express 
GS and GP which allows them to readily produce and store glycogen, or break 
it down if needed. Astrocytes also express very low levels of PDH compared to 
neurones, (Laughton et al., 2007), suggesting that astrocytes are more geared 
towards glycolysis than oxidative metabolism of glucose. During acute 
hypoglycaemic stimulus, the U373 cells may be maintaining lactate production 
by either increasing their capacity for glucose uptake, or by increasing glycogen 
breakdown.  
 
Noradrenaline further stimulated lactate production and release, suggesting that 
astrocytes have not yet reached their maximal glycogenolytic capacity during 
hypoglycaemia, but can be further stimulated to increase glycogenolysis. Other 
studies have shown that NA-mediated increase in glycogenolysis is glucose-
dependent, however these studies looked at hyperglycaemic levels of glucose 
and glucose analogues (5mM) (Cummins et al., 1983). From our studies we see 
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that euglycaemic and hypoglycaemic levels of glucose do not affect NA-
mediated lactate production. Previous studies have also shown NA causes an 
increase in pAMPK in brown adipose tissue (BAT) through UCP1 (Inokuma et 
al., 2005). This was not observed in our study. However this could be because, 
unlike BAT, where the main UCP isoform expressed in UCP1, this isoform is 
expressed at low levels in astrocytes (Lengacher et al., 2004; Perreten Lambert 
et al., 2014). During hypoglycaemia in humans a variety of hormones and 
neurotransmitters, such as adrenaline, noradrenaline and growth hormone are 
released. Our results indicate that following a reduction in glucose availability 
alone, astrocytes will work to maintain fuel provision to neurones by increasing 
lactate production efficiency. However, the input from hormones accompanying 
a hypoglycaemic episode may be able to stimulate this further. 
 
Following exposure to a 2-day recurrent hypoglycaemic stimulus, we observed 
a blunted pAMPK response to further hypoglycaemic stimulus, with the biggest 
difference observed at the 15 minute time point. This suggests a delayed 
activation of AMPK and could result in a delayed response to hypoglycaemia 
following recurrent hypoglycaemia, which may explain the reduced or delayed 
counter-regulatory response seen in people with T1D (Geddes et al., 2008). 
AMPK activity has previously been associated with impaired CRR, as AMPK 
activators can recover the CRR which is lost following RH in rats (McCrimmon 
et al., 2006). Even though AMPK phosphorylation was blunted following 
recurrent hypoglycaemic stimulus, pACC did not differ between cells exposed to 
a single or recurrent hypoglycaemic stimulus. This suggests that even though 
AMPK phosphorylation may be slightly blunted, its effect on its downstream 
target, ACC, is not affected. AMPK can be modulated through phosphorylation 
  
84 
 
by AMPKK, such as CaMKK and LKB1, or through allosteric activation by AMP, 
following changes in intracellular AMP:ATP ratio. This allosteric activation does 
not require phosphorylation of AMPK (Gowans et al., 2013). It is possible that in 
in our study we are observing a decreased phosphorylation of AMPK in 
response to a hypoglycaemic stimulus following RH, with, however, no change 
in AMPK activity. For a more definitive answer we could perform an AMPK 
activity assay rather than examining changes in protein phosphorylation alone. 
 
Following an acute hypoglycaemic stimulus, there was a non-significant trend 
for an increase in eATP at 15 and 30 minutes, which, at 30 min, was 
significantly larger than the response seen following a RH (Figure 3.3.1 & 
Figure 3.3.2). ATP release from astrocytes mediates the propagation of calcium 
waves, recruits microglia and modulates neuronal synaptic activity (Bowser and 
Khakh, 2004; Gourine et al., 2010; Idzko et al., 2014; Koizumi et al., 2003). The 
blunted ATP release following RH in astrocytes could affect the modulation of 
any or all of these, and thus may in part mediate the impaired CRR to 
hypoglycaemia.  We showed that astrocytes intrinsically respond to 
hypoglycaemia. However, in the brain, they would also receive signals such as 
hormones, cytokines and ATP from other cell types, such as microglia, which 
are likely to alter or enhance the astrocytic response. Microglial ATP release 
has been shown to stimulate astrocytes, which in turn amplifies this response 
(Pascual et al., 2012).  
 
No significant changes in GP phosphorylation were observed at 15 or 30 
minutes of hypoglycaemia, however there was a significant increase following 
180 minutes of the hypoglycaemic stimulus. It could be that at those earlier time 
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points, either astrocytic lactate production is maintained by increased glucose 
uptake for glycolysis rather than glycogenolysis, or that any changes in 
glycogen phosphorylase activation may be too small to be detectable. Another 
explanation is that glycogenolysis is being allosterically activated by AMPK. 
Evidence suggests that increases in AMPK activity can directly regulate 
glycogenolysis without changes in GP activity (Longnus et al., 2003; Polekhina 
et al., 2003).  Following prolonged hypoglycaemic stimulus (180min) there was 
a ~50% increase in phosphorylation of glycogen phosphorylase, indicating a 
large increase in the activity of this enzyme, and thus suggesting an increase in 
glycogenolysis. Our data suggests that during prolonged (180min) 
hypoglycaemia astrocytic glycogenolysis increases to produce and export more 
lactate, which is seen as an increase in pGP and an increase in lactate released 
per mol of glucose available. This is in agreement with multiple studies, 
suggesting that during periods of glucoprivation, such as hypoglycaemia or 
ischaemia, or high energy demand, such as exercise or learning, astrocytes 
produce and export lactate to support neuronal function (Brown et al., 2003; 
Matsui et al., 2015; Newman et al., 2011; Suh et al., 2007; Swanson and Choi, 
1993). 
 
Following the 2-day RH model, lactate falls faster in the RH group compared to 
H when compared to their respective controls. At 15 minutes there was no 
significant change in eLactate, and at 180 minutes both were significantly 
reduced, however at 30 minutes eLactate was only significantly reduced in the 
RH group. It is possible that in the H group glycolysis and/or glycogenolysis is 
initially increased to maintain extracellular lactate, which in a physiological 
setting, would supply fuel to neurones. This response could be delayed in the 
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RH group as a result of or in conjunction with the delay in AMPK activation. As 
discussed previously, AMPK activation in the VMH can reverse RH-induced 
impairment in the CRR (McCrimmon et al., 2006), and AMPK can allosterically 
modulate glycogenolysis (Longnus et al., 2003; Polekhina et al., 2003), 
suggesting that a blunted or delayed AMPK response following RH may be 
resulting in a decrease or delay in glycogenolysis, and thus, decrease in lactate 
production and export. In our model we did not observe any changes in basal 
eLactate levels, suggesting no changes in glycogen content. However, 
glycogen levels were not directly measured. To investigate whether glycogen 
supercompensation occurs in our model, a glycogen assay on cell lysates from 
C and RH cells, or a glucose uptake assay would need to be carried out. 
Another explanation would be that, in our model, we have astrocytes in 
isolation. In vivo or in a co-culture setting, neuronal signals may work to 
enhance astrocytic response to hypoglycaemia, or a hypoglycaemic stimulus. 
 
Our data shows that astrocytes intrinsically respond to low glucose. There is a 
moderate attenuation in the pAMPK, eATP and eLactate responses following 
RH. These small changes might be enhanced if astrocytes were exposed to CM 
from neuronal or microglial cultures exposed to RH. Neurones release a variety 
of neurotransmitters, such as glutamate, GABA and NA. Microglia also release 
a variety of gliotransmitters, such as ATP, which have been shown to modulate 
astrocytic signalling (Pascual et al., 2012), and cytokines. Small changes in the 
release of messengers from neurones and microglia may enhance or alter the 
intrinsic responses we observe in astrocytes following RH. 
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Chapter 4: Results 
4.1 AMPK pharmacology 
Introduction 
 
AMPK is a central regulator of whole body energy homeostasis, and has been 
shown to play an important role in the response to hypoglycaemia. 
Downregulation of AMPK in the VMH of rats causes a defective CRR to 
hypoglycaemia (McCrimmon et al., 2008). Similarly, intracerebroventricular 
administration of the AMPK inhibitor Compound C, or expression of dominant 
negative AMPK in the hypothalamus blunts the CRR to hypoglycaemia (Han et 
al., 2005). These findings, combined with the observation that antecedent 
hypoglycaemia causes a decrease in the hormonal CRR to further 
hypoglycaemia (McCrimmon et al., 2006) suggests that the blunted CRR 
observed in individuals with T1D with a history of frequent hypoglycaemic 
episodes may be mediated by changes in AMPK expression or activity. None of 
these studies showed that the relationship between AMPK and the CRR was 
specific to neurones; therefore, it is not unreasonable to speculate that this 
effect may also be mediated by astrocytes or microglia, or a combination of any 
or all of these three.  
 
Astrocytes play an important part in the CRR to hypoglycaemia. Inactivation of 
the glut2 gene results in an impaired glucagon response to hypoglycaemia 
which can be restored by re-expressing the gene in astrocytes alone (Marty et 
al., 2005). This is evidence that astrocytic GLUT2 expression is necessary for 
the glucagon response to hypoglycaemia without the need of neuronal GLUT2. 
Astrocytes also respond to RH by increasing glycogen storage (Alquier et al., 
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2007), known as glycogen supercompensation, which is thought to contribute to 
hypoglycaemia unawareness.  
 
Our studies showed that exposing astrocytes in culture to a hypoglycaemic 
stimulus for 15-180 minutes results in a robust increase in AMPK activation. 
This was blunted following exposure to antecedent hypoglycaemia (Figure 3.3), 
providing further evidence that astrocytic AMPK might be involved in the 
defective CRR seen in T1D. To investigate the effect of AMPK activation in 
astrocytes, AMPK activators with different mechanisms of action were used and 
the functional outcomes measured. Three common AMPK activators that were 
used in this study are A-769662, AICAR and dimethylbiguanide, more 
commonly known as metformin. 
 
A-769662 was developed by Cool et al (Cool et al., 2006) as a potential 
treatment for T2D. Thousands of compounds were screened until A-592107 
was identified to directly activate AMPK (Anderson et al., 2004b). Based on this 
compound the drug was further optimised to create A-769662. A-769662 
reversibly binds to AMPK, with specificity for β1 subunit-containing 
heterotrimers, to directly activate the enzyme. It also prevents AMPK 
dephosphorylation, making it a potent activator. It was screened for cross-
reactivity against at least 67 other receptors and ion channels, and was not 
shown to significantly cross-react with any at 10 µM. In this paper, it was used 
to concentrations up to 100 µM and was shown to have no cytotoxic effects in 
rat hepatocytes (Cool et al., 2006).  
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AICAR is a cell-permeable compound that due to its structural similarity to 
adenosine can enter most cells by competing for the adenosine transporter 
(Gadalla et al., 2004), where it is phosphorylated by adenosine kinase into 5-
Aminoimidazole-4-carboxamide ribotide (ZMP) (Vincent et al., 1996). ZMP is an 
analogue of AMP and can thus activate AMPK directly by binding to the γ 
subunit (Day et al., 2007). AICAR has been used extensively in research both in 
vivo and in vitro. Activating AMPK using AICAR in the VMH of rats was shown 
to amplify the CRR to hypoglycaemia (McCrimmon et al., 2004), and improve 
the counter-regulatory hormonal response to hypoglycaemia in rats previously 
exposed to RH (McCrimmon et al., 2006). This further supports the suggestion 
that AMPK may play an important part in the CRR to hypoglycaemia. 
 
Metformin is part of the biguanide family and is the first line of therapy for T2D; 
However its mechanism of action is still not fully understood (Rena et al., 2013). 
Although metformin was originally thought to mediate these effects through 
AMPK activation, more recent evidence has shown that AMPK is not essential 
for metformin’s anti-hyperglycaemic action (Foretz et al., 2010), suggesting its 
primary mode of action is through a still unknown mechanism. Metformin-
mediated AMPK activation may still be involved in some of its long-term effects, 
such as improved lipid metabolism. One potential mechanism of action that has 
received attention recently is metformin’s effect on mitochondrial Complex I (El-
Mir et al., 2000; Owen et al., 2000). Metformin has been shown to inhibit 
mitochondrial ATP production and oxygen uptake which results in an altered 
cellular AMP:ATP ratio (Hawley et al., 2010). The effects of metformin on AMPK 
activity are thus most likely the result of the changes in mitochondrial respiration 
and AMP concentration in the cell.  
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In this study we aim to characterise the response of astrocytes to an AMPK 
activator, in order to mimic the AMPK activation observed during a 
hypoglycaemic stimulus. 
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4.1.1 Both A-769662 and AICAR cause an increase in AMPK activation, but 
only A-769662 increases ATP release 
 
To investigate whether AMPK phosphorylation alters eATP and eLactate in 
astrocytes, three different AMPK activators, A-769662, AICAR and metformin 
were used at high concentrations, to ensure sufficient AMPK activation. U373 
cells were plated at 1,000,000 cells/dish in round, 10 cm dishes the day before 
the experiment. AMPK and ACC phosphorylation were measured to examine 
changes in AMPK activity, and eATP and eLactate were measured to establish 
whether they are regulated by AMPK activation in astrocytes.  
 
A-769662 (100µM) caused a 6.6±1.7-fold increase in AMPK phosphorylation 
after 30 minutes of treatment (Figure 4.1C; n=8; p<0.05) and 10.3 ± 2.0-fold 
increase after 3 hours of treatment (Figure 4.1D; n=7; p<0.01). AICAR (1mM) 
caused a small but significant increase in AMPK phosphorylation at both 30 
minutes (1.5 ± 0.1-fold) and 3 hours (1.9 ± 0.4-fold; Figure 4.1C; n=8; p<0.05; 
Figure 4.1D; n=7; p<0.05). There was a trend for a small increase in pAMPK 
when U373 cells were treated with metformin (1mM), but this did not reach 
significance (Figure 4.1C; n=8; p=0.0819; Figure 4.1D; n=7; p=0.0696). 
 
To determine whether altered AMPK phosphorylation resulted in increased 
activity, ACC phosphorylation was also measured. A-769662 induced a large, 
10.1 ± 2.1-fold increase in pACC at 30 minutes and 18.1 ± 5.2-fold at 3 hours 
(Figure 4.1E; n=9; p<0.01; Figure 4.1F; n=8; p<0.05). A more modest but 
significant increase in pACC was also observed following stimulation with 
AICAR for 30 minutes (2.3 ± 0.5-fold) and 3 hours (7.1 ± 2.0-fold; Figure 4.1E; 
n=9; p<0.05; Figure 4.1F; n=8; p<0.05). Metformin did not affect pACC. 
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Figure 4.1. A-769662 potently activates AMPK and stimulates ATP release in U373 cells. 
Representative Western blots of lysates of U373 cells treated with vehicle (0.1% DMSO), A-
769662 (100µM), AICAR (1mM) or Metformin (1mM) for 30min (A.) or 3hr (B.). Fold change in 
AMPK phosphorylation at 30min (C.; n=8) and at 3hr (D.; n=7). Fold change in phosphorylation 
of ACC at 30min (E.; n=9) and 3hr (F.;n=8). Extracellular ATP 30min (G.; n=9) and 3hr (H.; 
n=8) after treatment. Extracellular lactate 30min (I.; n=5) and 3hr (J.; n=7) after treatment. C-F. 
One sample t test. G-J. 1-way ANOVA with Bonferroni's multiple comparison test. * p≤0.05, ** 
p≤0.01 
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Extracellular ATP (eATP) was also measured from CM collected at the end of 
the 30 minute and 3 hour treatments. At 30 minutes, treatment with A-769662, a 
3.6-fold increase in eATP (from 36.3 ± 6.3 to 132.0 ± 35.0 pmol/ml) was 
observed (Figure 4.1G; n=9; p<0.01). At 3 hours a 2.7-fold increase (from 14.2 
± 2.4 to 38.2 ± 8.3 pmol/ml) in eATP was measured (Figure 4.1H; n=8; p<0.01). 
No change in eATP was observed with AICAR or metformin. 
 
Extracellular lactate was also measured in the CM. There was an increase in 
eLactate (3.8-fold increase from 15.53 ± 6.08 to 59.42 ± 15.55 nmol/mg) in the 
CM from A-769662-treated cells (30min; Figure 4.1I; n=5; p<0.01). Neither 
AICAR nor metformin altered eLactate at 30 minutes (Figure 4.1I), and none of 
the treatments had a significant effect at 3 hours (Figure 4.1J), suggesting that 
the A-769662-induced lactate release is a transient response. There was a 
much higher concentration of eLactate in the vehicle-treated group 3 hr after the 
treatment, compared to 30 min after treatment (Figure 4.1I&J). This is possibly 
due to lactate accumulation in the media. 
 
We showed that, in U373 cells, both A-769662 and AICAR significantly 
increased AMPK activity at 30min, whereas metformin had no effect even by 
3hr. Importantly, we also found that A-769662 caused a significant increase in 
eATP and eLactate within 30min, which is an effect that was not observed in 
any of the other AMPK activators used.  
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4.1.2 A-769662 causes a concentration-dependent increase in pAMPK and 
eATP in U373 cells and primary mouse astrocytes 
 
To determine whether the response of astrocytes to A-769662 was 
concentration-dependent, cells were treated with increasing concentrations of 
A-769662 for 30 minutes and the CM and lysates were collected for analysis. 
U373 cells and CRTAS were plated at 300,000 cells/well in 6-well a plate the 
day before the experiment. 
 
Western blotting analysis of U373 cells showed that A-769662 causes a 
concentration-dependent increase in pAMPK at concentrations above 50µM. 
AMPK phosphorylation was increased by 3.0 ± 0.8, 3.4 ± 0.9 and 4.7 ± 1.3-fold 
at A-769662 concentrations of 50, 75 and 100µM (Figure 4.2.1B; n=9; p<0.05). 
This corresponded to a concentration-dependent increase in pACC which was 
significantly increased by 2.6 ± 0.3-fold, 3.6 ± 0.6-fold, 4.7 ± 0.8-fold, 4.8 ± 0.8-
fold, and 6.3 ± 1.2-fold at A-769662 concentrations of 10, 25, 50, 75 and 100µM 
(Figure 4.2.1C; n=9; p<0.01). Analysis of eATP levels in CM showed there was 
a significant increase in eATP at 75µM and 100µM A-769662 from 130.4 ± 16.6 
to 232.1 ± 17.7 and 278.1 ± 34.3 pmol/ml respectively (Figure 4.2.1D; n=6; 
p<0.05). There was a modest, non-significant increase in eLactate levels 
between 10-75 M, which did not reach significance, potentially due to being 
underpowered (Figure 4.2.1E; n=4). 
 
We then performed the same study in CRTAS to determine whether the A-
769662-induced ATP release occurred in non-transformed cells. A trend for a 
concentration-dependent increase in pAMPK was observed which was not 
significant (Figure 4.2.2B), and a 1.7-fold, 1.9-fold and 1.9-fold increase in   
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Figure 4.2.1. A-769662 increases pAMPK, pACC, eATP and eLactate in a concentration-
dependent manner in U373 cells. A. Representative Western blots of U373 lysates of 
pAMPK and pACC following a 30min A-769662 concentration response (0-100µM). B. Fold 
change in AMPK phosphorylation (n=9). C. Fold change in ACC phosphorylation (n=9). D. 
Extracellular ATP following treatment (n=6). E. Extracellular lactate following treatment (n=4). 
B-E. 1-way ANOVA with Bonferroni's multiple comparison test. * p≤0.05, ** p≤0.01, *** p≤0.001 
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Figure 4.2.2. A-769662 increases pAMPK, pACC, eATP and eLactate in a concentration-
dependent manner in CRTAS. A. Representative Western blots of CRTAS lysates of pAMPK 
and pACC following a 30min A-769662 concentration response (0-100µM). B. Fold change in 
AMPK phosphorylation (n=4). C. Fold change in ACC phosphorylation (n=4). D. Extracellular 
ATP following treatment (n=9). E. Extracellular lactate following treatment (n=9). B-E. 1-way 
ANOVA with Bonferroni's multiple comparison test. * p≤0.05, ** p≤0.01, *** p≤0.001 
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pACC at 10, 50 and 100µM A-769662 (Figure 4.2.2C; n=4; p<0.05). A 
significant, 3.4-fold and 3.9-fold increase in eATP was observed at 75 and 
100µM A-769662 (Figure 4.2.2D; n=9; p<0.05). A significant, 1.7, 1.8 and 2.4-
fold increase in eLactate was observed at 50, 75 and 100 µM A-769662 (from 
77.45 ± 16.84 to 129.1 ± 29.99, 141.3 ± 26.32 and 182.2 ± 34.81 nmol/mg 
respectively; Figure 4.2.2E; n=9; p<0.05). 
 
This experiment showed a concentration-dependent increase in AMPK activity, 
as well as eATP and eLactate when using increasing concentrations of A-
769662 from 0-100µM in U373 cells. Extracellular ATP also increased in 
CRTAS at 75 and 100µM A-769662. 
 
4.1.3 AICAR enhances A-769662-mediated AMPK activation, but has no 
effect on eATP 
 
AICAR can enhance A-769662-mediated AMPK activation in primary 
hepatocytes (Ducommun et al., 2014). This prompted us to investigate whether 
it had a similar effect on astrocytes and the A-769662-mediated increase in 
eATP. U373 cells and CRTAS were plated at 450,000 cells/dish in round, 6 cm 
dishes the day before the experiment, and treated with A-769662 (50µM) ± 
AICAR (1mM) for 30 minutes before collecting the CM and lysates for analysis. 
This A-769662 concentration was selected as it caused a small but non-
significant increase in eATP after a 30 minute treatment in U373 cells, thus 
allowing us to see any potential increase in eATP (Figure 4.2). 
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Western blot analysis of U373 cell lysates treated with A-769662 or AICAR 
showed a 1.5 ± 0.1 or 1.6 ± 0.2-fold increase in pAMPK respectively (p<0.05). 
AMPK phosphorylation in lysates of cells treated with both A-769662 and 
AICAR was increased by 3.7 ± 0.6-fold compared to control and 2.5 and 2.4-
fold compared to A-769662 or AICAR treatment alone (Figure 4.3B; n=6; 
p<0.01). A-769662 treatment alone also caused a significant, 1.9-fold increase 
in eATP from 208.8 ± 19.4 to 404.4 ± 44.6 pmol/ml (p<0.001). As observed 
previously (Figure 4.1), AICAR treatment alone did not cause any changes in 
eATP. Extracellular ATP from U373 cells co-treated with A-769662 and AICAR 
(370.7 ± 15.4 pmol/ml) did not significantly differ from that of A-769662-treated 
(404.4 ± 44.6 pmol/ml) and was significantly higher than both vehicle-treated 
(208.8 ± 19.4 pmol/ml) and AICAR-treated (216.6 ± 27.7 pmol/ml) (Figure 4.3C; 
n=7; p<0.01). No significant changes in eLactate were observed with any of the 
above treatments (Figure 4.3D). The study was repeated in CRTAS, where 
similarly, A-769662 caused a significant, 2.9-fold increase in eATP from 22.8 ± 
5.2 to 65.3 ± 6.8 pmol/ml (n=3; p<0.05). No effect of AICAR on eATP was 
observed when used alone, or with the addition of A-769662. (Figure 4.3E). 
This study is in agreement with the study conducted by Ducommun et al, where 
they showed that A-769662 enhances AICAR-induced AMPK phosphorylation 
(Ducommun et al., 2014). Co-treating the cells with A-769662 and AICAR, 
however, had no effect on the A-769662-mediated increase in eATP. 
 
 
 
  
  
99 
 
 
  
Figure 4.3. Co-application of A-769662 and AICAR enhances pAMPK but not ATP 
release. A. Representative Western blots of pAMPK, Actin, pACC and total ACC of lysates of 
U373 cells treated with A-769662 (50µM) +/- AICAR (2mM) for 30min. B. Fold change in 
phosphorylation of AMPK in lysates of U373 cells at the end of the 30min treatment (n=6). C. 
Extracellular ATP at the end of the 30min treatment of U373 cells (n=7). D. Extracellular lactate 
at the end of the 30min treatment of U373 cells (n=7). E. Extracellular ATP at the end of the 
30min treatment of CRTAS (n=3). B-E. 1-way ANOVA with Bonferroni's multiple comparison 
test. * p≤0.05, ** p≤0.01, *** p≤0.001 
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4.1.4 A769662 enhances eATP and eLactate at both euglycaemic and 
hypoglycaemic conditions 
 
We previously observed that both hypoglycaemia and A-769662 treatment 
causes an increase in AMPK phosphorylation. A-769662 was also shown to 
cause an increase in eATP and lactate, whereas hypoglycaemia had a less 
consistent effect on eATP and caused a decrease in eLactate at the high SD  
(Figures 3.1G & 4.1). To study whether A-769662 affects the astrocytic 
response to hypoglycaemia, we treated cells with A-769662 (100µM) in 
euglycaemic (2.5mM glucose) or hypoglycaemic (0.1mM glucose) conditions for 
30 minutes before collecting CM and lysates for analysis. U373 cells and 
CRTAS were plated at 450,000 cells/dish in round, 6 cm dishes the day before 
the experiment. 
 
In the U373 cells treated with A-769662 in euglycaemic conditions, there was a 
1.8-fold increase in eATP from 234.3 ± 24.4 to 417.7 ± 40.6 pmol/ml (p<0.01)). 
A similar response was observed when cells were treated with A-769662 in 
hypoglycaemic conditions, with a 2-fold increase in eATP to 433.1 ± 37.4 
pmol/ml (Figure 4.4A; n=5; p<0.001). There was a 1.7-fold decrease in eLactate 
when comparing CM from 2.5 vs 0.1 mM glucose-treated cells from 159.4 ± 6.0 
nmol/mg to 95.81 ± 5.3 nmol/mg (p<0.001). This is comparable to the eLactate 
changes previously observed at the highest SD (1,000,000 cells/dish), but not to 
those observed at the medium SD (450,000 cells/dish; Figure 3.1F). This could 
be due to small differences in growth rate between experiments, due to 
passage number differences or unexpected variables during handling (eg. 
Room temperature or delays during plating). A-769662 increased eLactate 
levels in both euglycaemic (197.2 ± 14.7 nmol/mg) and hypoglycaemic (160.4 ±  
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Figure 4.4. A-769662 increases ATP and lactate release at both euglycaemic and 
hypoglycaemic conditions. A. Extracellular ATP at the end of a 30min treatment of U373 
cells with vehicle (0.1% DMSO) or A-769662 (100µM) in euglycaemic (2.5mM glucose) or 
hypoglycaemic (0.1mM glucose)  (n=5). B. Extracellular lactate at the end of the 30min 
treatment of U373 cells (n=6). C. Extracellular ATP at the end of the 30min treatment of 
CRTAS (n=5). D. Extracellular lactate at the end of the 30min treatment from CRTAS (n=5). 2-
way ANOVA with Bonferroni's multiple comparison test. * p≤0.05, ** p≤0.01, *** p≤0.001 
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12.8 nmol/mg) conditions by 1.2 and 1.7-fold respectively (Figure 4.4B; n=8; 
p<0.05).  
 
The study was repeated in CRTAS and a trend for an increase in eATP in A-
769662-treated cells was observed, but did not reach significance (Figure 4.4C; 
n=5). A-769662 caused a 2.5-fold increase in eLactate at euglycaemic (from  
225.3 ± 36.3 to 564.3 ± 87.6 nmol/mg) and 4.6-fold increase in hypoglycaemic 
conditions (from 117.9 ± 67.8 to 541.1 ± 130.8 nmol/mg; Figure 4.4D).  
 
This study shows that A-769662 increases eATP and eLactate in astrocytes 
independent of glucose availability. We can speculate that A-769662 may be 
having a direct effect on eATP and eLactate independent of low glucose-
induced AMPK phosphorylation. However a broader range of A-769662 
concentrations should be tested, to ensure submaximal activation by A-769662, 
and make any potential effects of hypoglycaemic stimulus apparent. 
 
4.1.5 Noradrenaline has an additive effect on A-769662-mediated increase 
in eLactate without affecting AMPK phosphorylation or eATP 
 
To investigate whether NA enhances any of the effects of A-769662 on eATP, 
and whether it has an additive effect on the A-769662-mediated increase of 
eLactate, U373 cells and CRTAS were exposed to A-769662 (100µM) ± NA 
(50µM) for 30min. The CM and lysates were collected at the end of the 
treatment for analysis. U373 cells and CRTAS were plated at 450,000 
cells/dishes, in round, 6 cm dishes the day before the experiment. 
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Figure 4.5. NA enhances the A-769662-mediated increase in eLactate. A. Representative 
Western blots of pAMPK, pACC, pGP and actin of lysates of U373 cells treated with A-769662 
(100µM) +/- NA (50µM) for 30min. B. U373: Fold change in AMPK phosphorylation (n=5). C. 
U373: Fold change of ACC phosphorylation (n=5). D. U373: Extracellular ATP at the end of the 
30min treatment (n=9). E. U373: Extracellular lactate at the end of the 30min treatment (n=6). 
F. CRTAS: Extracellular ATP at the end of the 30min treatment (n=6). G. CRTAS: Extracellular 
lactate at the end of the 30min treatment (n=6). B-C. One sample t test (hypothetical value of 
1). D-G. 1-way ANOVA with Bonferroni's multiple comparison test. * p≤0.05, ** p≤0.01, *** 
p≤0.001 
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In cell lysates of U373 cells treated with A-769662 alone, a 2.6 ± 0.5-fold 
increase in AMPK phosphorylation was observed when compared to the 
vehicle-treated (p<0.05). NA treatment alone had no significant effect on 
pAMPK. Co-treatment with A-769662 and NA resulted in a 2.2 ± 0.5-fold 
increase from control (Figure 4.5B; n=5; p<0.05). ACC phosphorylation was 
also increased 10.4 ± 1.6-fold with A-769662 treatment alone (p<0.01). NA 
caused a small (1.4 ± 0.1-fold) but significant increase in ACC phosphorylation 
(p<0.05). Co-application of the two drugs resulted in a 7.7 ± 1.1-fold increase in 
pACC (Figure 4.5C; n=5; p<0.01). A-769662, as observed previously (Figure 
4.1) resulted in a significant, 2-fold increase in eATP from 219.3 ± 62.0 nmol/ml 
to 453.1 ± 99.1 pmol/ml (p<0.01). A similar increase in eATP was observed with 
the co-treatment of cells with both A-769662 and NA (453.7 ± 219.1 pmol/ml; 
n=9; p<0.01). NA treatment alone had no effect on eATP (Figure 4.5D). A-
769662 caused a trend for an increase in eLactate in U373 cells (from 243.0 ± 
26.6 to 309.7 ± 39.3 nmol/ml); however, this did not reach significance. NA 
caused a 1.8-fold increase in eLactate to 196.5 ± 14.7 nmol/mg (p<0.05) and 
co-treating with A-769662 and NA enhanced eLactate levels further to 459.8 ± 
44.6 nmol/mg (Figure 4.5E; n=6; p<0.001). 
 
In CRTAS, A-769662 induced a significant increase in eATP from 39.1 ± 19.2 to 
105.0 ± 49.7 pmol/ml (p<0.05). A similar increase was observed with the co-
treatment of A-769662 and NA (102.7 ± 39.4 pmol/ml; n=6; p<0.05). NA 
treatment on its own had no significant effect on eATP (Figure 4.5F). A-769662 
also caused a significant increase in eLactate from 157.2 ± 59.6 to 570.9 ± 87.3 
nmol/mg (p<0.01). NA resulted in a similar increase in eLactate to 601.5 ± 67.1 
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nmol/mg (p<0.01) and co-application with the two drugs caused a further 
increase in eLactate to 1076 ± 169.5 nmol/mg (Figure 4.5G; n=6; p<0.001). 
 
As previously shown, NA had no effect on eATP, and this study showed that it 
did not have any effect on A-769662-induced increases on eATP either. 
However, A-769662 had additive effect on NA-induced eLactate in both U373 
and CRTAS.  
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4.2 Understanding the mechanism of A-769662-mediated ATP release 
Introduction 
 
In our studies, A-769662 caused an increase in eATP in astrocytes (Figure 4.1). 
A-769662 is an AMPK activator commonly used in research to improve our 
understanding on AMPK activity. It is therefore important to understand the 
mechanism responsible for the A-769662-mediated increase in eATP, and 
whether it is a direct result of AMPK activation. 
 
ATP is the universal “danger signal” and acts as a pro-inflammatory mediator, 
as well as a fast excitatory neurotransmitter, or long-term mediator of 
proliferation, growth and development (Burnstock, 2006b; Idzko et al., 2014). In 
astrocytes, ATP has also been shown to be crucial for calcium wave 
propagation amongst astrocytes (Bowser and Khakh, 2007; Cotrina et al., 
1998). Most tissues and cell types express multiple purinergic receptors (P2R), 
which are activated by ATP and its by-product, ADP, as well as other 
nucleotides, such as UTP, UDP and UDP-glucose (Idzko et al., 2014), which 
suggests alterations in ATP release could have significant effects on 
surrounding cells and tissues. 
 
ATP can be released from cells passively, as a result of damage to the cell 
walls, or actively in response to a stimulus. Some of the mechanisms behind 
ATP release suggested in literature are through hemichannels or gap junctions 
(Cotrina et al., 1998; Garre et al., 2010), P2X7 receptors (Suadicani et al., 
2006), large-conductance anion channels (Anderson et al., 2004a), or through 
vesicles (Bowser and Khakh, 2007; Lalo et al., 2014). Following release, ATP is 
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rapidly broken down by extracellular ectonucleases into ADP, AMP and 
adenosine. These can also act as intercellular messengers to elicit a response, 
for example through activation of P2Y or adenosine receptors, or they can be 
taken back up into the cell and be recycled (Idzko et al., 2014). 
 
ATP is found at a much higher concentration in the cell, compared to the 
extracellular compartment. This means that upon damage to the cell 
membrane, ATP is passively released from the cell following a diffusion 
gradient. This triggers an inflammatory response, recruiting microglia to the 
area and causing phagocytosis of the damaged cell (Idzko et al., 2014). This is 
a non-regulated form of ATP release from cells.  
 
ATP can also be released in a more regulated manner, through hemichannels. 
Hemichannels are formed by connexins or pannexins organised in a hexamer, 
embedded in the cell membrane, which allows small molecules, such as ATP, 
Ca2+ and certain dyes to move across the cell membrane. Hemichannels 
formed by connexins are called connexons, and pannexins called pannexons. 
Connexons in the cell membrane of adjacent cells can join to form gap junctions 
that allow intercellular exchange (Bennett et al., 2003; Giaume et al., 2010; 
Lazarowski et al., 2011). Astrocytes mainly express connexin 43 and connexin 
30 (Dermietzel et al., 1991; Giaume et al., 1991) of which connexin 43 in the 
mediobasal hypothalamus has been shown to play a role in glucosensing and 
insulin secretion (Allard et al., 2014). 
 
The P2X7 receptor is a purinergic receptor thought to be associated with a 
variety of pathologies, such as temporal lobe epilepsy, neurodegenerative 
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disorders such as Alzheimer’s disease, neuropathic pain, diabetes, and certain 
cancers (Burnstock, 2006a). The P2X7 receptor differs from most purinergic 
receptors in that, once activated by high concentrations of ATP, the P2X7R 
transitions from a channel to a pore (Surprenant et al., 1996). This allows larger 
molecules (up to 1kDa) to move through the membrane and results in Ca2+ and 
Na+ influx and K+ efflux. This pore opening is associated with a variety of 
physiological and pathophysiological functions, including cell lysis and 
apoptosis (He et al., 2017; Surprenant et al., 1996), as well as mediating 
inflammation and immunity (Arulkumaran et al., 2011). 
 
Astrocytes have been shown to release ATP through calcium-induced vesicular 
exocytosis (Bowser and Khakh, 2007; Lalo et al., 2014), although this is still 
controversial (Hamilton and Attwell, 2010). ATP release has been shown to be 
necessary for calcium wave propagation following mechanical stimulation in 
astrocytes (Bowser and Khakh, 2007).  
 
In this study we aim to examine the underlying mechanism behind the A-
769662-mediated increase in eATP. 
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4.2.1 Blocking gap junctions does not attenuate the A-769662-mediated 
increase in eATP 
 
To investigate whether the A-769662-mediated increase in eATP is due to 
increased ATP release through gap junctions, the gap junction inhibitor, 
carbenoxolone was used.  U373 cells and CRTAS, were pretreated with 
carbenoxolone before being treated with A-769662, and total, intracellular and 
extracellular ATP (tATP, iATP and eATP respectively) were measured. For 
eATP measurements, U373 cells and CRTAS were plated at 450,000 cell/dish 
in round, 6 cm dishes, the day before the experiment. For tATP and iATP 
measurements, U373 cells were plated at 20,000 cells/well in a black, 96-well 
plate the day before the experiment. 
 
In U373 cells pre-treated with carbenoxolone (100µM; 30min), followed by a 30 
minute treatment with A-769662 (100µM) showed no significant change in tATP 
or iATP. There was a small, non-significant trend for an increase in tATP and 
iATP in cells treated with A-769662 (100µM) alone (13% and 11% from control 
respectively) (Figure 4.6A&B). 
 
U373 cells treated with A-769662 (100µM) showed a 2.6-fold increase in eATP 
when comparing to vehicle-treated (from 97.6±17.9, to 249.1 ± 34.3 pmol/ml; 
p<0.05). Pre-treating U373 cells with carbenoxolone (100µM) resulted in a 
further 1.7-fold increase in eATP following a 30 minute A-769662 (100µM) 
treatment, from 249.1±34.4 to 413.7±55.8pmol/ml, compared to A-769662 
treatment alone (p<0.05). No significant change in eATP were observed in the 
cells that received carbenoxolone treatment alone (Figure 4.6C; n=5). CRTAS 
treated with A-769662 (100µM) alone, showed a 7.8-fold increase in eATP  
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Figure 4.6. Carbenoxolone did not attenuate the A-769662-evoked ATP release. A. Total 
ATP (normalised to control) at the end of a 30min pre-treatment of U373 cells with A-769662 
(100µM), with a 30min carbenoxolone (100µM) pre-incubation (n=3). B. Intracellular ATP 
(normalised to control) at the end the treatment in U373 cells (n=3). C. Extracellular ATP at the 
end the treatment in U373 cells (n=5). D. Extracellular ATP at the end of the treatment in 
CRTAS (n=5). A-D. 1-way ANOVA with Bonferroni's multiple comparison test. * p≤0.05, ** 
p≤0.01, *** p≤0.001 
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when compared to vehicle-treated, from 4.0 ± 0.8 to 30.8 ± 6.2 pmol/ml (Figure 
4.6D; n=5; p<0.01). These studies suggest that gap junctions are unlikely to 
play a role in the A-769662-induced increase in eATP.  
 
4.2.2 Imaging of acidic vesicles in astrocytes using quinacrine 
 
To examine whether the increase in eATP observed following the treatment of 
astrocytes with A-769662 was mediated through increased vesicular release of 
ATP, cells were loaded with quinacrine, and changes in fluorescence intensity 
in individual cells following treatment with A-769662 (100µM) was measured 
(cells plated at 80,000 cells/dish in round, glass-bottomed, 4 cm dishes for 
quinacrine imaging, and at 450,000 cells/dish in round, 6 cm dishes for eATP 
measurements the day before the experiment).  Quinacrine is an antimalarial 
drug that, in live cells, accumulates in acidic vesicles. This is commonly used to 
image lysosomes or ATP-containing vesicles, it is not, however, a direct 
measure of ATP release (Akopova et al., 2012; Bodin and Burnstock, 2001; 
Haanes et al., 2014; Kasymov et al., 2013; Pangrsic et al., 2007; Pierzynska-
Mach et al., 2014).  
 
Using Protocol 1 (Chapter 2.2.7), a gradual decrease in fluorescence intensity 
was observed following addition of vehicle or A-769662. A trend for a decrease 
in fluorescence was observed in both cells treated with A-769662 (100uM) or 
vehicle (0.1% DMSO) from the time of drug addition (Figure 4.7A). We were 
concerned that this decrease in fluorescence from addition of treatment may be 
the result of cellular stress, and might be masking the effect of A-769662. The 
protocol was revised, and the experiment was repeated using Protocol 2  
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Figure 4.7. No change in fluorescence was observed with A-769662 using Quinacrine. A. 
Percent change in fluorescence, measured using protocol 1 (see Chapter 2.2.7), in U373 cells 
pre-incubated with Quinacrine (1µM) measured over 30min, with A-769662 (100µM) or vehicle 
(0.1% DMSO) added at t=10min (Vehicle n=9, A-769662 n=11). B. Percent change in 
fluorescence, measured using protocol 2 (see Chapter 2.2.7) in U373 cells (Vehicle n=2, A-
769662 n=3). C. Percent change in fluorescence, measured using protocol 2 (see Chapter 
2.2.7) in CRTAS (n=2). D. Extracellular ATP in U373 cells at the end of a 30min A-769662 
(100µM) after a 15min Quinacrine (1µM) pre-incubation followed by a 15min wash step (n=5). 
2-way ANOVA with Bonferroni's multiple comparison test.  * p≤0.05, ** p≤0.01, *** p≤0.001 
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(Chapter 2.2.7). No change in fluorescence was observed using this protocol 
either (Figure 4.7B&C).  
 
To ensure the experimental conditions did not affect the A-769662-mediated 
increase in eATP, cells were plated in normal dishes and loaded with 
Quinacrine for 15 minutes in 2.5mM glucose serum-free, phenol red-free DMEM 
with 25mM HEPES. The dye was then washed off as in the imaging 
experiments, and the cells were treated with A-769662 (100µM) for 30min. The 
CM was collected and eATP measured.  As observed previously, A-769662 
caused an increase in eATP, but this was a smaller increase than in previous 
experiments. A-769662 (100µM) for 30 minutes in U373 cells in previous 
experiments resulted in a 3.6-fold increase in eATP (Figure 4.1G), whereas in 
U373 cells prepared as for Quinacrine imaging, without loading the cells with 
dye, only a 1.3-fold increase was observed. Similarly, cells loaded with 
Quinacrine dye only showed a 1.6-fold increase in eATP after A-769662 
treatment (Figure 4.7D).   
 
These experiments were inconclusive, and did not prove or rule out A-769662-
mediated vesicular ATP release, they did however suggest that this method 
may not be suitable for this experiment. Different approaches should be 
investigated, for example using different reagents such as MANT-ATP for 
imaging vesicular ATP release, or using a set-up that allows for control of 
atmospheric conditions, such as CO2, and thus does not require HEPES for 
buffering the media. 
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4.2.3   A-769662 increases intracellular calcium in astrocytes 
 
Vesicular release of ATP from astrocytes is commonly driven by an increase in 
[Ca2+]i. To investigate whether ATP release is driven by changes in [Ca
2+]i, 
U373 cells and primary astrocytes were loaded with the [Ca2+]i dye Fluo4 direct, 
and treated with A-769662 (100µM) whilst recording changes in fluorescence 
(plated at 20,000 cells/well in a clear 96-well plate the day before the 
experiment). 
 
Treating U373 cells with A-769662 caused a 1.4-fold increase in [Ca2+]i (Figure 
4.8A). The area under the curve (AUC) increased by 5.1-fold following A-
769662 treatment (Figure 4.8B; p<0.01; n=3). In CRTAS, the change in [Ca2+]i 
was less than that observed in the U373 cells, with a 1.1-fold increase in peak 
response following A-769662 treatment (Figure 4.8C). However, the increase 
was sustained during the recording period, giving a 6.4-fold increase in the AUC 
(Figure 4.8D; p<0.05; n=4). In primary hypothalamic astrocytes (HTAS) a 1.3-
fold increase in peak response was observed (Figure 4.8E), with a 9.7-fold 
increase in the area under the curve (Figure 4.8F; p<0.05; n=4). 
 
In all three cell types (U373, CRTAS and HTAS), a rapid increase in [Ca2+]i was 
observed following application of A-769662 (100µM) . These data suggests that 
the A-769662-mediated increase in eATP may be by changes in [Ca2+]i. 
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Figure 4.8. A-769662 causes an increase in intracellular calcium. A. Relative fluorescence 
units from U373 cells treated with vehicle (0.1% DMSO), or A-769662 (100µM) at t=30s (n=3). 
B. Total area under the curve for the two treatment groups generated from figure A. C. Relative 
fluorescence units of the above experiment carried out in CRTAS (n=4).  D. Total area under 
the curve for the two treatment groups generated from figure C.  E. Relative fluorescence units 
of the above experiment carried out in HTAS (n=4). F. Total area under the curve for the two 
treatment groups generated from figure E. A, C, E. 2-way ANOVA with Bonferroni's multiple 
comparison test. B, D, F. Unpaired t test. * p≤0.05, ** p≤0.01, *** p≤0.001 
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4.2.4   Extracellular calcium is not required for the A-769662-mediated 
increase in eATP 
 
As shown in the previous experiment, treating astrocytes with A-769662 causes 
a rapid and persistent increase in [Ca2+]i (Figure 4.8). To investigate whether 
the increase in [Ca2+]i is a result of calcium entry into the cell, U373 cells (plated 
at 450,000 cells/dish, in round, 6 cm dishes the day bfore the rxperiment), as 
well as primary mouse astrocytes, were treated with A-769662 in a calcium-free 
saline buffer (Table 1). U373 cells, CRTAS and HTAS were plated at 450,000 
cells/dish in round, 6 cm dishes the day before, the experiment. 
 
In U373 cells, treated with A-769662 (100µM) in normal saline (NS), a 2.3-fold 
increase in eATP was observed which is comparable to the previously-observed 
effect of A-769662 (Figure 4.1; p<0.01). This indicates that replacing SF DMEM 
with NS for this experiment has no obvious effects on A-769662-induced ATP 
release. Treating U373 cells in a calcium-free saline did not have an effect on 
baseline eATP (112.4 ± 23 in NS and 104.4 ± 18.7 pmol/ml in calcium-free 
saline), or on the A-769662-mediated eATP response (2.2-fold increase from 
baseline; Figure 4.9A; p<0.01; n=5). 
 
CRTAS treated in calcium-free saline showed a 2-fold increase in baseline 
eATP from 9.3 ± 2.5 to 19 ± 3.5 pmol/ml when compared to those treated in NS. 
The eATP from CRTAS treated with A-769662 (100µM) in NS increased by 3.5-
fold (p<0.05) and those treated in calcium-free saline by 2.5-fold (Figure 4.9B; 
p<0.01; 6). HTAS treated in NS and calcium-free saline showed a similar trend, 
where baseline eATP was raised by 1.8-fold in those in calcium-free when  
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Figure 4.9. Extracellular calcium is not required for the A-769662-mediated increase in 
eATP. A. Extracellular ATP of samples collected from U373 cells treated with A-769662 
(100µM) or vehicle (0.1% DMSO) for 30min in Normal saline or calcium free saline (n=5). B. 
Extracellular ATP from CRTAS treated as above (n=6). C. Extracellular ATP from CRTAS at 
the end of the treatment (n=8). 2-way ANOVA with Bonferroni's multiple comparison test.  * 
p≤0.05, ** p≤0.01, *** p≤0.001 
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compared to those in NS. In the HTAS treated in NS, a 2.8-fold increase in 
eATP was observed following the 30 minute treatment with A-769662, which 
was not significantly different from the 2.1-fold increase observed when the cells 
were treated in calcium-free saline (Figure 4.9C; p<0.05; n=8). Primary 
astrocytes were more sensitive to the removal of extracellular calcium, as, in 
both CRTAS and HTAS astrocytes, an increase in baseline eATP was 
observed; However, the A-769662-mediated increase in eATP persisted. 
Therefore, entry of extracellular calcium is not required for A-769662-mediated 
increase in eATP.  
 
4.2.5   Chelating intracellular calcium causes a decrease in the A-769662-
mediated increase in eATP in primary astrocytes 
 
To investigate whether release of intracellular calcium stores drives the A-
769662-mediated increase in eATP, U373 cells, CRTAS and HTAS (plated at 
450,000 cells/dish, in round, 6 cm dishes the day before the experiment) were 
treated with the intracellular calcium chelator, BAPTA-AM (25-50µM), for 30 
minutes prior to the A-769662 treatment (100µM). Total ATP, as well as the 
intracellular ATP/ADP ratio were also measured to determine whether A-
769662 and BAPTA-AM affect internal energy status (cells plated at 20,000 
cells/well, in black, 96-well plates the day before the experiment).  
 
Treating U373 cells with A-769662 (100µM) following a 30 minute pre-treatment 
with BAPTA-AM (25µM) resulted in a 2.3-fold increase in eATP, which is 
comparable to the 2.4-fold increase seen without BAPTA-AM pre-treatment 
(n=6; p<0.01). There was no difference in baseline eATP between the vehicle-
treated cells (105.0 ± 8 pmol/ml) and the cells treated with BAPTA alone (117.0 
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± 9.3 pmol/ml; Figure 4.10A). To ensure sufficient [Ca2+]i chelation, a higher 
concentration of BAPTA was used. There was no significant effect of BAPTA on 
baseline eATP (101.6 ± 9.2 vs 97.9 ± 12.5 pmol/ml), nor was there any change 
in A-769662-induced increase in eATP (Figure 4.10B; n=8). Treating U373 cells 
with A-769662 or BAPTA had no effect on tATP or ATP/ADP ratio (Figure 
4.10C&D; n=6). 
 
CRTAS treated with A-769662 showed a significant 2.7-fold increase in eATP 
(p<0.05). There was no significant difference in the baseline eATP in cells 
treated with vehicle vs BAPTA-AM (50µM; 27.5 ± 10.8 vs 23 ± 8.5 pmol/ml). 
There was a trend for an increase in eATP in CRTAS pre-treated with BAPTA 
followed by A-769662 treatment (1.8-fold), which did not reach significance 
(Figure 4.10E). 
 
In HTAS, treatment with A-769662 alone caused a 2.9-fold increase in eATP, 
from 23 ± 5.8 to 65.8 ± 8 pmol/ml. Treating these cells with BAPTA-AM caused 
a 2.6-fold decrease in eATP from 23.01 ± 5.8 to 8.9 ± 4.7 pmol/ml. The eATP 
response to A-769662 following BAPTA-AM pre-treatment was reduced 
significantly by 1.9-fold (34.6 ± 6.2 pmol/ml) when compared to that with A-
769662 alone (65.8 ± 8 pmol/ml) (Figure 4.10F; n=5; p<0.05). 
 
From this data we see a small attenuation in the A-769662-mediated increase in 
eATP after BAPTA-AM treatment (50µM) in primary astrocytes, suggesting that 
release of calcium from intracellular stores may, at least in part, be responsible 
for A-769662-induced ATP release (Figure 4.10).  
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Figure 4.10. Chelating intracellular calcium attenuates the A-769662 mediated ATP 
release in primary astrocytes. A. Extracellular ATP at the end of a 30min treatment of U373 
cells with A-769662 (100µM) or vehicle (0.1% DMSO) +/- 30min pre-treatment with BAPTA 
(25µM) (n=6). B. Extracellular ATP from U373 cells at the end of a 30min treatment with A-
769662 (100µM) or vehicle (0.1% DMSO) +/- 30min pre-treatment with BAPTA (50µM) (n=8). 
C. Fold change in total ATP compared to control at the end of the 30min treatment (n=6). D. 
ATP:ADP ratio in U373 cells at the end of the 30min treatment (n=6). E. Extracellular ATP at 
the end of the 30min treatment in CRTAS (n=6). F. Extracellular ATP at the end of the 30min 
treatment in HTAS (n=5). 1-way ANOVA with Bonferroni's multiple comparison test. * p≤0.05, 
** p≤0.01, *** p≤0.001 
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4.2.6   A-769662 causes an increase in eATP and intracellular calcium in 
AMPK knockout cells 
 
To investigate whether the A-769662 effect on eATP is a result of direct AMPK 
activation, we used MEF WT and α1/α2 AMPK KO cells. MEF WT and MEF 
α1/α2 AMPK KO cells were exposed to increasing concentrations of A-769662 
for 30 minutes and eATP was measured in both cell types (plated at 450,000 
cells/dish in round, 6 cm dishes, plated the day before the experiment). Cells 
were also plated in 96-well plates to measure tATP (1,000 cells/well in black 
plates) and [Ca2+]I (20,000 cells/well in clear plates). Treating MEF WT cells 
with increasing A-769662 concentrations (10-100µM) for 30 minutes resulted in 
a concentration-dependent increase in AMPK phosphorylation. This effect was 
absent in the MEF α1/α2 AMPK KO cells, where no pAMPK was detected 
(Figure 4.11A).  
 
A concentration-dependent increase in eATP was also observed in the MEF WT 
cells between A-769662 concentrations of 25 to 100µM. In the MEF WT cells, 
eATP following a 30 minute treatment with A-769662 concentrations of 25, 50, 
75 and 100µM, increased by 1.6, 3.1, 4.6 and 5.1-fold from vehicle respectively, 
which was significantly different from vehicle-treated at 100µM A-769662. 
(Figure 4.11B). In the KO cells, eATP increased by 2.2, 6.7, 8.6 and 10-fold 
when treated with 25, 50, 75 and 100µM A-769662 compared to vehicle, which 
was significant at 75 and 100µM (Figure 4.11C; n=3; p<0.05).  Baseline eATP in 
the MEF α1/α2 AMPK KO cells was 9.1-fold lower than that of the MEF WT 
cells (69.3 ± 18.9 in WT and 7.6 ± 1.4 pmol/ml in KO). Total ATP in untreated 
MEF WT cells was 1.9-fold higher than that of MEF α1/α2 AMPK KO cells 
(Figure 4.11E; n=4; p<0.05; Completed by Craig Beall, included here for  
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Figure 4.11. A-769662 increases ATP release and intracellular calcium in α1/α2 AMPK 
KO MEF cells. A. Representative blots of pAMPK in lysates of MEF WT or α1/α2 AMPK KO 
cells treated with increasing concentrations of A-769662 for 30min. B. Extracellular ATP at the 
end of the experiment above conducted in MEF WT cells (n=3). C. Extracellular ATP at the end 
of the experiment above conducted in MEF α1/α2 AMPK KO cells (n=3). D. Graph representing 
the combined data from figures B and C normalised to 100% using their respective controls 
(n=3). E. Total ATP in MEF WT and α1/α2 AMPK KO cells (n=4). F. Relative fluorescence units 
from MEF α1/ α2 AMPK KO cells treated with vehicle (0.1% DMSO) or A-769662 (100µM) at 
t=30 (n=3). G. Total area under the curve for the two treatment groups generated from figure F. 
(n=3). A-B. 1-way ANOVA with Bonferroni's multiple comparison test. E&G. Unpaired t test. F. 
2-way ANOVA with Bonferroni's multiple comparison test. * p≤0.05, ** p≤0.01, *** p≤0.001 
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completion). This change in tATP is not sufficient to explain the decrease in 
baseline eATP observed. 
 
MEF α1/α2 AMPK KO cells exposed to A-769662 (100µM), displayed a trend 
for an increase in [Ca2+]i peak response (1.2-fold) and AUC (4.6-fold) when 
compared to vehicle-treated cells, which was not significant (Figure 4.11F&G; 
n=3; p=0.1077; Completed by Aman Malhi, included here for completion). This 
study is underpowered and more data would be needed to complete it. 
 
This study showed that, despite the absence of functional AMPK, A-769662 still 
induced a concentration-dependent increase in eATP and [Ca2+]i in MEF α1/α2 
AMPK KO cells. This shows that certain aspects of the A-769662 effect on cells 
may be AMPK-independent. 
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4.3 Discussion 
 
A-769662, AICAR and Metformin are well used pharmacological agents acting 
through distinctly different mechanisms (Guigas et al., 2009; Rena et al., 2013). 
Our first aim was to investigate the actions of these drugs on astrocytes in vitro, 
to identify an appropriate drug to imitate AMPK activation during 
hypoglycaemia. 
 
A-769662 acts to directly activate AMPK and prevent its dephosphorylation, 
making it a potent AMPK activator (Cool et al., 2006). AICAR on the other hand 
enters the cell and is phosphorylated to ZMP which acts as an AMP mimic, 
directly binding to the γ-subunit to activate AMPK (Day et al., 2007). This 
difference in AMPK activation mechanism between these two drugs could 
explain the difference in potency. Metformin has not been shown to directly 
activate AMPK, and it’s mechanism of action is not yet fully understood (Rena 
et al., 2013). 
 
Our studies show that A-769662 is indeed the most potent AMPK activator out 
of the three tested, and acts to strongly activate AMPK in a concentration-
dependent manner (Figure 4.2.1). AICAR activated AMPK, although to a much 
lesser degree when compared to A-769662. Both compounds also caused a 
significant increase in ACC phosphorylation, one of the downstream targets of 
AMPK, indicating they both increase AMPK activity and not just 
phosphorylation. Metformin had no significant effect on AMPK or ACC 
phosphorylation at the concentration and time points used in this study. 
Previous studies on primary astrocytes have shown effects of metformin on 
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glycolysis at a concentration of 10mM for 2 hours (Westhaus et al., 2015) and 
on ketogenesis at a concentration of 1mM for 24 hours (Takahashi et al., 2014). 
It is possible that a longer incubation or higher concentration was required for 
sufficient metformin action in our experiments. It is not known if U373 cells 
express the organic cation transporter 1 (OCT1), one of the most recognised 
mechanisms for uptake of metformin, which would require a longer incubation 
time, as seen in other OCT1-deficient cell lines like HEK293, which require a 16 
hour incubation (Hawley et al., 2010). 
 
A-769662 also caused a large increase in eATP initially suggesting that AMPK 
activation may be driving ATP release from these cells. The same effect of A-
769662 on eATP was observed in both U373 cells and CRTAS, demonstrating 
that this effect is not specific to U373 cells. Unlike A-769662, AICAR did not 
alter eATP. It is possible that AICAR may be acting to prevent increase in ATP 
release through changes in intracellular ATP or ADP:ATP ratio. Studies 
disagree on whether AICAR alters intracellular energy stores, and some show 
no effect on the ADP:ATP ratio (Gadalla et al., 2004; Hawley et al., 2010). 
Others studies, however, show a decrease in total ATP, which could be 
responsible for masking changes in eATP (Craig Beall, personal 
communication, unpublished). Another explanation might be that A-769662 
induces ATP release through an AMPK-independent mechanism, as indicated 
by later experiments. 
 
The eATP in the CM at the end of the 3 hour treatment was lower than that in 
the 30 minute treatment. The increased volume of media used in the 3 hour 
treatments alone is not enough to explain the 2.5-fold lower eATP. The smaller 
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volume in the 30 minute treatments may be leading to an increase in [eATP], 
which in turn may be driving ATP-induced ATP release. It is possible this effect 
is lost in the 3 hour experiment, where the higher media volume may be diluting 
the original [eATP]. We performed a pilot study using Bz-ATP to measure ATP-
induced ATP release, however this drug was found to interact with the assay 
used to measure eATP. Another, non-hydrolysable ATP analogue would need 
to be used to measure ATP-induced ATP release. Another explanation for the 
difference between the 30 minute and 3-hour CM eATP could be the action of 
ecto-nucleotidases. Preliminary studies we performed showed indications of 
regulated ecto-nucleotidase activity in astrocyte cultures, whereby eATP was 
greatly increased in euglycaemic compared to hypoglycaemic conditions in the 
presence of the eATPase inhibitor ARL 67156. This indicates that eATPases 
are present in our astrocytic cultures, and their activity can be regulated 
depending on conditions. This means that, following the 3 hour incubation in our 
experiments, eATPase activity might be upregulated, resulting in a reduced 
eATP accumulation compared to our 30 minute controls. 
 
A-769662 treatment also caused an increase in eLactate. Extracellular lactate 
as well as AMPK activity have been shown to play an important role in the CRR. 
VMH lactate infusion decreases the CRR to hypoglycaemia (Borg et al., 2003) 
and raises VMH GABA (Zhou et al., 2010). Suppression in VMH GABA 
signalling is necessary for the release of glucagon and adrenaline, and initiation 
of the CRR (Zhou et al., 2010), something that is prevented by an increase in 
VMH lactate. Whilst lactate can be transferred across the brain-blood barrier, it 
can also be produced by astrocytes in conditions of high energy demand 
(Pellerin and Magistretti, 2012). Astrocytes are highly glycolytic and are geared 
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towards lactate production. They highly express glucose transporters, as well as 
LDH1 and 5, making them highly efficient at glucose uptake and subsequent 
conversion to lactate which can be exported out of the cell through MCT 1, 2 
and 4. Alternatively, GS and GP expression allow for glucose conversion into 
glycogen for storage which can be broken down when necessary. Energy stress 
causes AMPK activation, therefore it is plausible that AMPK activation in 
astrocytes may be driving lactate production and release to support neuronal 
function. As with the changes observed in eATP, AICAR seemed to have no 
significant effect on eLactate. If this increase in eLactate is a result of AMPK 
activation, it is possible that the lack of response with AICAR treatment is due to 
insufficient AMPK activation. Changes in eLactate are only observed following 
100µM A-769662, which also causes a 6.6-fold increase in pAMPK. AICAR 
(1mM) only caused a 1.5-fold increase in pAMPK, which may not be sufficient to 
alter lactate production and release (Figure 4.1C&I). It is also possible that this 
is another AMPK-independent effect of A-769662. 
 
Extracellular lactate is much higher at the end of a 3 hour time point when 
compared to the 30 minute time point. This is possibly due to lactate 
accumulating in the media over time. The cells in all treatment groups should 
have an equivalent amount of glycogen stored and capacity for glycogen and 
glucose breakdown at the beginning of the experiment, as they come from a 
homogeneous cell population which has been treated identically up to the point 
of plating for experiments. This means that by the end of the 3 hour stimulation, 
all cells might have already produced and released the maximum amount of 
lactate before running low on glycogen, or before auto-inhibition of lactate 
production and release. Unpublished data from our lab has shown that following 
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a 3 hour treatment of primary astrocytes with A-769662 (100µM) causes a 
decrease in GP and increase in GS activity (Craig Beall, personal 
communication, unpublished), which would lead to an increase in glucose 
conversion to glycogen, and decrease in glycogen breakdown. The trend for a 
decrease in eLactate in the 3 hour A-769662 treatment may be a reflection of 
this.  
 
Co-treatment of astrocytes with A-769662 and AICAR showed a further 
enhancement of AMPK phosphorylation. This agrees with previous literature, 
where small concentrations of A-769662 were shown to significantly enhance 
AICAR-induced AMPK activation (Ducommun et al., 2014). In agreement to 
previous findings, this study suggests A-769662 and AICAR activate AMPK 
through separate mechanisms. It also suggests that the changes in eATP are 
independent of AMPK activation, as supported later by the MEF α1/α2 AMPK 
KO experiments (Figure 4.11), as there was no further increase in eATP 
following co-treatment with both drugs compared to A-769662 alone. This would 
suggest A-769662 may be targeting a separate, AMPK-independent 
mechanism to mediate its effect on eATP. 
 
Cells were also treated with A-769662 in euglycaemic and hypoglycaemic 
conditions, to see whether A-769662 and hypoglycaemia-mediated AMPK 
activation have an additive effect on eATP. There was no difference in eATP in 
cells treated with A-769662 at euglycaemic vs hypoglycaemic conditions, 
suggesting that hypoglycaemia-induced increase in pAMPK, and energy status 
of the cells do not affect A-769662-mediated ATP release. We also examined 
eLactate to see whether energy status would limit the A-769662-mediated 
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increase in lactate release. As observed previously, low glucose caused a 
decrease in eLactate. Even though eLactate following A-769662 treatment in 
hypoglycaemic was lower than that in euglycaemic conditions, the A-769662-
mediated fold-increase in eLactate was greater in hypoglycaemic (1.5-fold) than 
euglycaemic conditions (1.2-fold). This indicates that the A-769662-mediated 
increase in eLactate is not dependant on glucose availability. This increase in 
eLactate could be the result of A-769662 increasing glucose uptake, glycolysis, 
glycogenolysis, lactate production or lactate transport. AMPK activation is 
known to increase glucose uptake and glycolysis (Carling, 2004). Studies have 
suggested that A-769662 also causes an increase in glucose uptake in certain 
cell types, including muscle in an AMPK-independent mechanism (Treebak et 
al., 2009), which may explain the further increase we observed with A-769662 
treatment in hypoglycaemia.  
 
We showed that co-treatment of cells with both A-769662 and NA, resulted in 
an increase in eLactate much greater than either drug alone. NA has not been 
shown to increase pAMPK in our studies or other published research in 
astrocytes. This additive effect of the two drugs with the lack of AMPK activation 
suggests that they are likely to be causing this increase in eLactate through 
different pathways rather than competing for the same pathway to increase 
lactate production and export. NA is known to increase glycogenolysis in cells 
(Gibbs, 2015; Subbarao and Hertz, 1990). AMPK activation is known to 
increase glucose uptake and processing into glycogen (Carling, 2004) and 
AMPK ablation in astrocytes has been shown to prevent nitric oxide or 
oligomycin-induced increases in lactate release (Almeida et al., 2004). We can 
speculate that A-769662 may be causing this increase in eLactate by increasing 
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glycolysis through AMPK activation, while NA increases eLactate through an 
increase in glycogenolysis. Evidence suggests A-769662 causes an increase in 
glucose uptake in muscle, through an AMPK-independent mechanism involving 
PI3-kinase (Treebak et al., 2009). If this is also true in astrocytes, this could 
further increase their capacity for lactate production. 
 
From our studies it was not clear whether A-769662-induced ATP release was 
through vesicular exocytosis. The data showed no significant difference 
between fluorescence intensity in vehicle-treated or A-769662-treated cells. 
However, the eATP using the conditions used in the quinacrine imaging 
protocol, where phenol red-free DMEM with HEPES was used, was reduced 
compared to that observed with the protocol used in most of our CM 
experiments using the phenol red-containing DMEM without HEPES (Figure 
4.7). To investigate whether HEPES attenuates the A-769662-mediated 
increase in eATP, the experiment would need to be repeated using an imaging 
chamber buffered with CO2. Another option would be to try a different method of 
detecting changes in vesicular ATP, such as loading the cells with the 
fluorescent ATP analogue mant-ATP. 
 
Carbenoxolone did not reduce the A-769662-mediated increase in eATP. In 
U373 cells, contrary to our predictions, carbenoxolone pre-treatment enhanced 
the A-769662-mediated increase in eATP (Figure 4.6C), something previously 
observed in brain slices (Frenguelli et al., 2007). A study on endothelial cells 
showed that a 6 hour treatment with Carbenoxolone (100µM) caused a marked 
increase in Cx43 expression at both protein and RNA level, and altered 
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distribution within cells (Sagar and Larson, 2006). Since the main connexins 
expressed in astrocytes are Cx43 and Cx30 (Dermietzel et al., 1991; Giaume et 
al., 1991; Giaume et al., 2010), it is not unreasonable to speculate that 
carbenoxolone treatment of U373 cells results in a compensatory increase in 
Cx43 expression. There is a scarcity of data on which gap junctions 
carbenoxolone may have a higher affinity for, although studies indicate that it 
has a high affinity for pannexins and much lower affinity for connexins 
(Bruzzone et al., 2005). Blocking gap junctions in primary astrocytes did not 
affect A-769662-mediated ATP release (Figure 4.6). Preliminary studies have 
indicated to a higher expression of Cx43 in U373 cells compared to CRTAS 
(data not shown), which might explain the differences observed in these two cell 
lines following A-769662 treatment with a carbenoxolone pre-treatment. This 
difference in Cx43 expression may also partially explain the lower baseline 
eATP observed in the CRTAS compared to U373 cells. The lack of an 
attenuation of the A-769662-mediated increase in eATP in CRTAS would 
suggest that ATP in this case is not released through gap junctions. Apart from 
the lower affinity of carbenoxolone for connexins and the evidence suggesting it 
upregulates Cx43 expression, studies also suggest that it blocks VRAC 
(Benfenati et al., 2009) and P2X7 receptors (Suadicani et al., 2006). A different 
gap junction blocker should be used to verify these findings, such as the Cx43-
selective blocker, TAT-Gap19. Western blotting could be used to examine 
differences in Cx43 expression in U373 cells following carbenoxolone 
treatment. 
 
We have shown that A-769662 (75-100uM) causes a significant increase in 
eATP in astrocytes (U373 and CRTAS) (Figure 4.2.1D & 4.2.2D). Furthermore, 
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treating astrocytes with A-769662 (100µM) also resulted in a significant 
increase in [Ca2+]i (Figure 4.8). Taken together, this data suggests that this 
increase in eATP may be driven by an increase in [Ca2+]i caused by the drug. 
Increases in [Ca2+]i have previously been shown to induce vesicular ATP 
release from astrocytes (Bowser and Khakh, 2007). Data concerning the 
mechanism behind ATP release from astrocytes is conflicting. Some studies 
suggest that ATP release is mediated through vesicular exocytosis (Lalo et al., 
2014), whereas others suggest not, but that ATP is released through 
hemichannels (Cotrina et al., 1998; Garre et al., 2010), P2X7 receptors 
(Suadicani et al., 2006), VRAC (Anderson et al., 2004a), or CFTR (Schwiebert 
et al., 1995). 
 
Increases in [Ca2+]i can be through several different mechanisms. Intracellular 
calcium can increase through more influx from the extracellular media. In order 
to investigate whether this was the source of [Ca2+]i observed after A-769662 
stimulation, the experiment was repeated in calcium-free media. This had effect 
on the U373 cell line, but lack of extracellular calcium raised baseline eATP in 
CRTAS (Figure 4.9). Removal of extracellular calcium is a stressful stimulus, 
and since ATP is a universal danger signal it is possible that it evokes a 
response in astrocytes. Reduction in extracellular calcium has been shown to 
cause an increase in [Ca2+]I in astrocytes in culture, in a phospholipase C-
dependant mechanism, involving inositol triphosphate (IP3) and the release of 
ATP (Stout and Charles, 2003; Zanotti and Charles, 1997). This could explain 
the effect we observed in the CRTAS. One main difference between the CRTAS 
and U373 is that the latter is a transformed cell line, which means they may be 
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lacking one or more constituents required for this mechanism, which would 
explain the difference observed between the two cell types. Increased mTOR 
and S6K1 have been implicated in the tumorigenesis of U373 cells (Nakamura 
et al., 2008). Our lab has also shown a constitutively active PKB in U373 cells 
(unpublished data, Craig Beall, personal communication). This suggests there 
may be a mutation upstream of PKB, such as phosphoinositide 3-kinase (PI3K), 
which could explain the differences observed. In fact, it has been shown that a 
hallmark of astrogliomas is a deregulation of the PI3K pathway (Cancer 
Genome Atlas Research, 2008). Regarding A-769662 stimulation; there was no 
significant attenuation of the increase in the extracellular ATP in either cell 
types, suggesting that extracellular calcium is not involved in the drug’s effect 
on ATP release. 
 
Another mechanism by which intracellular calcium can be increased is through 
release of intracellular calcium stores. To investigate that, we used the 
intracellular calcium chelator, BAPTA-AM. Chelating intracellular calcium 
caused a small decrease in ATP release following treatment with A-769662 in 
the U373 cells and a much larger decrease in CRTAS. This had the biggest 
effect in HTAS, where there was a significant decrease in ATP release following 
A-769662 treatment, however, BAPTA-AM seems to also have an effect on 
extracellular ATP at baseline in these cells (Figure 4.10). In our studies, primary 
astrocyte eATP was decreased with treatment of BAPTA-AM alone. This 
contradicts other studies which have shown an increase in ATP release 
following BAPTA-AM treatment in CRTAS (Anderson et al., 2004a). This 
observed result could be the result of differences in methodology. BAPTA-AM 
  
134 
 
was also shown to decrease intracellular ATP in CRTAS (Anderson et al., 
2004a). In our studies, tATP and ATP:ADP ratio were only measured in U373 
cells, where BAPTA-AM had no effect on baseline eATP, tATP or ATP:ADP. 
This may be different in the CRTAS; However it was not measured in the 
current study. Most astroglioma cells show overactivation of the PI3K pathway, 
which is involved in [Ca2+]i mobilisation (Cancer Genome Atlas Research, 
2008), which may be responsible for the differences we observe between U373 
cells and primary astrocytes regarding [Ca2+]i chelation.  This could also be the 
result of the comparably higher (~4 times higher) baseline eATP of U373 cells 
compared to the primary astrocytes masking the effect of chelating intracellular 
or removing extracellular calcium. 
 
To investigate whether the effect observed of A-769662 treatment on astrocytes 
is a result of AMPK activation, the studies were repeated in MEF α1/α2 AMPK 
KO cells. The increase in intracellular calcium as well as the increase in 
extracellular ATP was preserved in the MEF α1/α2 AMPK KO cells following 
stimulation with A-769662 (Figure 4.11). This indicates that whether the 
increase in intracellular calcium and eATP are related or not, neither are a result 
of AMPK activity. It is possible that A-769662 targets an AMPK-independent 
pathway which results in the release of intracellular calcium stores, driving ATP 
release from the cell. This is an effect of A-769662 that has not previously been 
reported. Whilst some studies have previously indicated A-769662 may have 
AMPK-independent effects, none of them looked at eATP. Moreno et al showed 
an increase in 26S proteasome activity in MEF cells and an increase in toxicity 
and apoptosis following a treatment with A-769662, both of which were AMPK-
independent (Moreno et al., 2008). Treeback et al reported PI3K-dependent 
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increase in glucose uptake in muscle that was AMPK-independent (Treebak et 
al., 2009). This suggests A-769662 may have AMPK-independent effects on 
cellular function. It is important to note that in these experiments high 
concentrations of A-769662 were used. During the original identification and 
characterisation of A-769662, the EC50 was determined to be in the low µM 
range for the tissues examined (<10µM), and any cross-reactivity was studied 
at 10µM (Cool et al., 2006). In our experiments the effects of A-769662 on 
eATP and [Ca2+]i were observed at concentrations from 50µM and above, which 
would suggest that A-769662 has off-target effects at higher concentrations. 
Many studies use A-769662 at concentrations above 100µM, which raises the 
question of whether the effects they are observing are a result of AMPK 
activation as suggested. It is important to report this off-target effect of high 
concentrations of A-769662 on eATP, as eATP is an inflammatory mediator, 
which can then act on purinergic receptors to induce cytokine release and 
immune responses. Some of the effects of A-769662 observed in studies using 
high concentrations may not be the result of AMPK activation, but of 
inflammatory and immune responses mediated by this increase in eATP, 
therefore, care must be taken when interpreting data obtained using this drug. 
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Chapter 5: Conclusions 
 
Whole body energy homeostasis is regulated through both peripheral as well as 
central organs, with the hypothalamus being one of the most important central 
regulators of energy homeostasis. The central response to hypoglycaemia 
undergoes maladaptive changes following RH which result in impaired CRR to 
hypoglycaemia (Arbelaez et al., 2008; LaGamma et al., 2014; McCrimmon et 
al., 2006; Segel et al., 2002). Whilst both glucosensing neurones, and 
astrocytes are in part involved in the hormonal response to hypoglycaemia, the 
majority of studies only focus on glucosensing neurones, or whole brain areas, 
with little work on astrocytes specifically. The aim of this study was to 
investigate whether astrocytes can intrinsically detect and respond to 
hypoglycaemia, and whether RH results in adaptive responses in astrocytic 
gliotransmission. 
 
AMPK activity in the VMH has been implicated in the development of impaired 
CRR to hypoglycaemia, where inhibition results in blunted counter regulation of 
hypoglycaemia (Han et al., 2005; McCrimmon et al., 2008), and activation can 
reverse RH-induced impairment in the CRR to hypoglycaemia (McCrimmon et 
al., 2006; McCrimmon et al., 2004). The role of AMPK in neurones, particularly 
glucosensing neurones in the VMH, has been well-characterised (Beall et al., 
2012b; Taib et al., 2013); However the role of AMPK in astrocytes has not been 
extensively studied. In this study hypoglycaemia caused an increase in 
astrocytic pAMPK. This response is common across most cells and acts on 
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downstream targets to decrease anabolic and increase catabolic processes, 
thus conserving energy (Taib et al., 2013).  
 
During exposure to hypoglycaemic conditions, astrocytes maintained eLactate 
levels for at least 15min. At the later time points (30, 180min), eLactate 
decreased; However, this decrease did not reflect the decrease in glucose 
availability, even following 180min. This suggests that astrocytes can maintain 
lactate production and export even in prolonged hypoglycaemic conditions. This 
is likely mediated through increased glucose uptake and glycolysis, both of 
which can be a direct result of AMPK activation (Carling, 2004), as well as 
through increased glycogenolysis. It is important to bear in mind that in this 
study there is no lactate demand from neurones, which could potentially drive 
astrocytic lactate production and release in vivo or in a co-culture set-up.  
 
During hypoglycaemia, astrocytes are likely to be exposed to a variety of 
hormones, in addition to a decrease in glucose availability. For example, during 
hypoglycaemia, NA is released from the hindbrain directly to the hypothalamus 
(Palkovits et al., 1980). Our study showed that exposing astrocytes to NA in 
euglycaemic and hypoglycaemic conditions causes a large increase in 
eLactate, indicating that astrocytic lactate production and export can be further 
stimulated by NA during a hypoglycaemic stimulus. Although not directly 
addressed in the current study, this increased lactate production may be a 
result of increased glycogenolysis by NA, in conjunction with increased glucose 
uptake and/or glycolysis as a result of increased AMPK activity during 
hypoglycaemic conditions. 
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Our study showed that astrocytes intrinsically respond to hypoglycaemic 
conditions. The next step was to investigate whether these responses change 
following exposure to RH. Following RH, there was a blunted pAMPK response 
to further hypoglycaemia although this did not translate to changes in lactate 
release following RH. In other tissues, AMPK activation increases glucose 
uptake and glycolysis (Carling, 2004), therefore a decrease in eLactate would 
be expected if AMPK activation is blunted. It is possible that the attenuated 
pAMPK response to hypoglycaemia is not sufficient to cause a significant 
change in eLactate. Another potential explanation is that, according to the 
glycogen supercompensation hypothesis, cells exposed to RH may have a 
larger glycogen store (Canada et al., 2011; Oz et al., 2009), allowing increased 
lactate production through glycogenolysis. An important additional study would 
be to measure glycogen content following RH. If there are no changes in 
glycogen storage in astrocytes following RH, a co-culture of astrocytes with 
neurones may prove a more representative model, as it would account for any 
substances released by neurones, and would provide astrocytes with a lactate 
demand from the neurones during hypoglycaemic conditions. 
 
Despite there not being a significant change in eATP during a single 
hypoglycaemic stimulus, there was a trend for an increase. This small increase 
was significantly attenuated following RH. Accurately measuring eATP is 
challenging, as eATPases can rapidly break down eATP (Zimmermann et al., 
2012). This means that taking measurements at specific time points can result 
in a high variability in the resulting eATP measurements, masking small 
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changes. A more effective way of measuring eATP during a hypoglycaemic 
stimulus, is using biosensors (Llaudet et al., 2005), which can take a real-time 
measure of eATP. This can be used in cultured cells, or in brain slices. Using 
ATP biosensors in brain slices would also take into account neuronal signalling 
onto astrocytes, which may enhance or blunt the changes in eATP observed 
during hypoglycaemic stimulus. Astrocytes respond to changes in their 
environment, as well as neuronal and other glial transmission. Glucosensing 
neurones respond to hypoglycaemic stimulus by releasing a variety of 
neurotransmitters and hormones, such as NA, ACTH and glucocorticoid 
(Palkovits et al., 1980; Watts and Donovan, 2010). The exposure of astrocytes 
to these at the same time as the hypoglycaemic stimulus could alter the eATP 
response to hypoglycaemia. Extracellular ATP is a universal danger signal and 
neuromodulator (Idzko et al., 2014) through activation of purinergic receptors. 
This leads to increases in [Ca2+]I and can cause calcium wave propagation 
amongst astrocytes (Bowser and Khakh, 2007; Cotrina et al., 1998). ATP can 
also lead to cytokine release and recruitment of microglia (Idzko et al., 2014). 
Therefore, the blunted eATP response to hypoglycaemia could result in blunted 
ATP-induced ATP release and diminished calcium wave propagation. The next 
step in this study could be the investigation of calcium wave propagation 
following RH. Astrocytic cytokine release following RH could also be studied, as 
well as microglial recruitment.  
 
To investigate whether the blunted eATP response following RH was a result of 
the attenuated pAMPK response, a variety of AMPK activating drugs were used 
and pAMPK and eATP were measured.  Of the three AMPK activators tested, 
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only A-769662 resulted in an increase in eATP in a concentration-dependent 
manner. Co-application of A-769662 and AICAR enhanced AMPK activation as 
shown previously (Ducommun et al., 2014), but it had no further effect on eATP, 
suggesting the changes in eATP observed are not a result of AMPK activation, 
as later confirmed using MEF α1/α2 AMPK KO model. Similarly, exposing 
astrocytes to a hypoglycaemic stimulus in the presence of A-769662 had no 
further effect on the A-769662-mediated increase in eATP. Treating MEF α1/α2 
AMPK KO cells to A-769662 also resulted in a concentration-dependent 
increase in eATP, further supporting the hypothesis that changes in eATP 
observed during drug treatment or low glucose are not a result of AMPK 
activation. 
 
It is important to point out that in our experiments, A-769662 resulted in AMPK-
independent changes in eATP as well as [Ca2+]i. Whilst A-769662 has been 
thought of as one of the most potent and specific AMPK activators, our studies 
suggest that it may have AMPK-independent effects, which could result in 
inflammatory signalling as a result of the increased eATP (Idzko et al., 2014). 
This may lead to incorrect conclusions from studies using this drug at 
concentrations of 50 μM and higher, if the assumption is that all results obtained 
are due to direct AMPK activation. There have been a several studies the past 
few years suggesting that A-769662 may mediate some of its effects through 
AMPK-independent mechanisms, specifically on glucose uptake (Treebak et al., 
2009) and proteosomal activity (Moreno et al., 2008); However this mechanism 
has not yet been identified. Our studies suggest that the changes observed in 
eATP were not a result of ATP release through gap junctions, and were not 
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driven by the influx of calcium from the extracellular space. There was some 
inhibition following chelation of intracellular calcium stores, suggesting that A-
769662 may be triggering the release of intracellular stores, resulting in ATP 
release. 
 
In conclusion, we have shown that astrocytes intrinsically detect and respond to 
a hypoglycaemic stimulus, measured through an increase in AMPK activation. 
The resulting increase in pAMPK and eATP, are moderately blunted following 
RH. We have further shown that the changes in pAMPK and eATP following a 
hypoglycaemic or pharmacological stimulus are two independent processes. 
This led us to the discovery that the well-known AMPK activating drug A-
769662, has an AMPK-independent effect on eATP and [Ca2+]i, which may 
influence the interpretation of data obtained using this drug. The mechanism 
behind A-769662-induced increase in eATP is still unknown, but may involve 
release of calcium from intracellular stores.  
 
This is the first study to report on the effects of RH on human as well as primary 
mouse astrocytes. Further studies on glycogen storage, cytokine release, 
calcium wave propagation and microglial recruitment would allow us to 
determine what impact these changes may have on cell-to-cell interactions. 
Investigating the effect of RH in astrocyte-neuron co-cultures would allow us to 
study this further and determine the molecular adaptations in both, and how 
these interact. Further studies would also be required to determine what target 
A-769662 mediates its effects on eATP and [Ca2+]i through, to enable better 
interpretation of results using this drug. 
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